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B Abstract 
The degeneracy of the genetic code with its 61 codons encoding for only 20 amino acids is the basis 
for a phenomenon known as codon usage bias. That means that different organisms show differences 
in the frequency of occurrence of synonymous codons. Despite the necessity of HIV to use the host’s 
translational machinery for viral gene expression, the virus exhibits an adenine-rich nucleotide 
composition which differs clearly from the GC-rich coding regions of humans. Changing the 
nucleotide composition by choosing synonymous codons at certain positions might therefore impact 
viral replication by affecting viral gene expression. Previous studies of our group showed that 
adapting the gag gene to human codon usage (huGag) led not only to a significantly increased protein 
production but also caused independency of Rev, an accessory protein of HIV that exports intron-
containing viral mRNAs. The aim of this work was to gain insight into the effects of codon adaptation, 
especially regarding length and position, and the associated impact on gag expression. For this, 
subgenomic gag reporter constructs were generated that systematically varied the humanized part 
of the gene. Those constructs were then transfected into HEK293T cells. Gag expression was 
investigated on protein level by p24 ELISA as well as on RNA level by qPCR. Furthermore, transcription 
efficiency as well as RNA stability were analyzed using nuclear run-on and actinomycin D assays. It 
was observed that increasing the length of the humanized sequence starting from the 5’ end directly 
correlated with p24 and gag mRNA levels. Contrary to that, such a correlation was lacking for 
constructs humanized progressively in 3’ to 5’ direction. It became apparent that humanization of 
the 5’ end of gag is necessary for enhanced protein production and Rev-independent expression. In 
addition, it was found that a short sequence, surrounding the nucleotides 61-75 of gag in the 5’-part 
of the gene contains a specific inhibitory motif which affects transcription rate as well as RNA 
stability. Moreover, the expression pattern of the different variants was analyzed under the control 
of a heterologous CMV promoter as well as an LTR promoter of HIV-1. For both systems, comparable 
expression patterns were observed. By PCR analysis of reverse transcribed RNA from transfected 
cells, as well as northern blot analysis, the generation of cryptic splicing variants was excluded. 
Further, a second reporter gene was used in order to investigate whether the function of the 
identified inhibitory motif could be transferred. For this, a quasi-lentiviral system was used to express 
egfp after its adaptation to human and HI-viral codon usage. It became apparent that the inhibitory 
effect of the identified motif was only transferable when it was embedded in a larger part of wild-
type gag. The influence of the inhibitory motif on HIV gag expression as well as the missing inhibitory 
effect on egfp could be based on characteristics of the mRNA secondary structures. For gag, but not 
for egfp variants, presence of the motif had a clearly destabilizing effect in mRNA folding predictions, 
which might influence protein binding of the RNA degradation machinery. In future experiments an 
examination of this hypothesis would be eligible and helpful to gain further insight in the connection 
between altered codon usage and gene expression.   
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C Introduction 
 The human immunodeficiency virus -1 (HIV-1) 
C.1.1 Epidemiology 
Despite intensive research for more than 30 years [2] and accompanying major advances in medical 
treatment, the infection with the immunodeficiency virus (HIV) still represents a life threatening 
situation for millions of people. Untreated, an HIV infection leads to the Acquired Immune Deficiency 
Syndrome known as AIDS. The course of this disease is typically characterized by three phases. Firstly, 
infected people show influenza-like symptoms caused by a high viremia and a rapid decline in CD4-
positive T-cells [3]. The second phase is a symptom-free state, often mediated by a T-cell driven 
immune response against HIV [4]. Lastly, the continuous depletion of CD4-positive T-cells leads to an 
increase in viral load. This phase is generally linked to opportunistic infections and tumors, which are 
typically for the disease pattern of AIDS [5].  
The adequate availability of Antiretroviral Therapy (ART) still is a problem in some areas of the world. 
So, despite constantly increasing ART coverage over time, in 2017 only about 21 million patients of 
the estimated 37million infected people are receiving an adequate therapy, which accounts for only 
around 60%. Especially in Western and Central Africa and the Eastern Mediterranean, ART coverage 
is not satisfactory with 29% or even 18% of HIV positive men and 48% and 19% of HIV positive women 
receiving ART, as shown in Figure C-1[1].  
 
Figure C-1: Accessibility of antiretroviral treatment to HIV positive individuals 
Development of the numbers of ART-receiving people worldwide (left) and ART coverage for males and females in 
different WHO regions. Modified after [1]. In 2017 only 21.7 million of the estimated 37 million HIV-infected people 
received ART. Especially people in Western & Central Africa as well as the Eastern Mediterranean were not supplied with 
an adequate therapy.  
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HIV-1 can be classified into the four Groups M, N, O and P which arose through zoonotic 
transmissions of the chimpanzee simian immunodeficiency virus (SIVCPZ) or gorilla immunodeficiency 
virus (SIVGOR) to humans [6]–[8]. Group M, which causes most of the infections, can be divided into 
nine clades (A-D, F-H, J and K). Besides HIV-1, there is also the human immunodeficiency virus type 2 
(HIV-2), which is predominantly found in West African nations, though increasing numbers of 
infections have been recognized also in other parts of the world. The modes of transmission are equal 
to those of HIV-1, namely sexual contact, blood-borne exposure (blood transfusion, shared needles), 
and perinatal transmission [9]. 
C.1.2 Structure of HIV-1 
HIV-1 is a member of the lentiviruses which belong to the viral family retroviridae. Because of the 
intensive research over the last decades most questions regarding the general structural features as 
well as the viral replication have been solved and can be reviewed in different excellent publications, 
books and reviews from which the following information are derived [10]–[15]. A characteristic 
feature of retroviruses is the reverse transcription of their RNA genome in double-stranded DNA, 
followed by the integration into the host’s genome. Infectious HIV-1 particles contain a membrane 
which is derived from the host’s cell membrane and encircles a conic capsid. Furthermore, the viral 
membrane contains the envelope protein (Env), which is the only viral protein that is present at the 
particle’s surface and consists of gp120 and gp41. The matrix protein (MA, p17) is bound inside of 
the membrane by an N-terminally attached myristoyl group. The conic capsid is formed only by the 
p24 capsid protein (CA) and contains the viral enzymes reverse transcriptase (RT), protease (PR), 
integrase (IN) as well as the viral genome [10]–[15].  
 
Figure C-2: Schematic structure of an HIV particle (modified after [10]) 
The lipid membrane of HIV is derived from the host’s plasma membrane by budding of the virus and contains the only 
viral surface molecules gp41 and gp120. Inside of the lipid membrane the matrix protein (MA, p17) is attached. Inside of 
the conic capsid which is built by the capsid protein (CA, p24) the two identical RNA copies are complexed with 
nucleocapsid proteins (NC, p7). Furthermore, the capsid contains the viral enzymes reverse transcriptase (RT), integrase 
(IN) and protease (PR).  
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C.1.3 The life cycle of HIV-1  
The initial adsorption of the viral particle to the cells is mediated by an interaction of the external 
glycoprotein gp120 to the CD4 receptor of the target cell e.g. T-helper cells, monocytes, macrophages 
and dendritic cells. This event is followed by a conformational change of the gp120 protein which 
allows the interaction with either the CCR5 or CXCR4 chemokine receptor. These processes enhance 
the binding affinity between virus and cell surface which allows the fusion of the membranes and 
therefore enables the entry into the cell. This is followed by uncoating and reverse transcription of 
the viral RNA genome in double-stranded DNA, which generates the long terminal repeats at both 
ends of the genome (see below). The RNA part gets degraded during this process by the RNase-H 
function of the reverse transcriptase. The double-stranded DNA molecule is transported into the 
nucleus as a pre-integration complex (PIC) together with associated cellular and viral proteins like 
the integrase, Vpr and matrix protein (p17). A phosphorylated form of p17 stays connected with the 
pre-integration complex and allows, together with the Vpr protein and cellular nuclear import 
factors, the transport of the reverse-transcribed genome through the nuclear pores, which enables 
 
Figure C-3: Replication cycle of HIV-1 (from [16]) 
Initial binding of HIV to the target cell is mediated by interaction of gp120 and the CD4 receptor of the host cell. After a 
conformational change an additional interaction with the chemokine receptor CXCR4 or CCR5 occurs. This allows the 
fusion of the membranes of the virus and the host cell, which is followed by uncoating and reverse transcription of the 
viral genome in double-stranded DNA. The reverse-transcribed genome is transported with cellular and viral proteins as 
a pre-integration complex into the nucleus. The viral protein integrase mediates the integration of the viral genome into 
the host's genome, followed by transcription. The transcribed viral RNAs are used for protein synthesis and as viral 
genomes for progeny virions.  
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the infection of non-dividing cells. Inside the nucleus the viral integrase mediates the integration of 
the genome at an unspecific position, followed by transcription of viral RNAs. The different classes of 
transcripts are used either for protein synthesis or as viral genomes for progeny virions [16]–[20]. 
C.1.4 Genome organization and viral gene expression 
HIV-1 contains two identical copies of (+)-sense, single-stranded RNA molecules in a complex with 
nucleocapsid proteins (NC, p7).  Since the two RNA molecules have a 5’ cap as well as 3’ 
polyadenylation, they show typical features of a eukaryotic mRNA. The genome of HIV-1 (as shown 
in Figure C-4) has a size of about 9700 nucleotides which encode for structural genes (gag, pol and 
env) as well as regulatory and accessory genes (tat, rev, nef, vif, vpr and vpu). After reverse 
transcription of the RNA into double-stranded DNA, and following degradation of the viral RNA, the 
proviral DNA is generated by integration into the human genome. During that process, long terminal 
repeats (LTRs) are generated which contain all cis-active sequences as well as promoter and enhancer 
elements which control the retroviral gene expression. The viral genes get transcribed by the cellular 
DNA-dependend RNA polymerase and are expressed from partially overlapping open reading frames. 
Lastly, after alternative splicing, the mRNAs get translated by the cellular translation machinery.[10], 
[21].  
 
Figure C-4: Schematic structure and organization of the HIV-1 genome: 
During integration, long terminal repeats (LTRs) are generated. The structural genes gag, pol and env are shown in yellow, 
whereas regulatory and accessory genes are depicted in grey. The open reading frames of tat and rev are encoded by two 
exons each.  
The produced transcripts of HIV during infection can be classified into three groups. Shortly after 
infection, only short, completely spliced mRNAs are produced which encode the regulatory viral 
proteins Tat, Nef and Rev. Over time, the transcription rate gets strongly enhanced and incompletely 
spliced mRNAs are produced. Those mRNAs encode the envelope protein (Env) as well as the 
accessory proteins Vif, Vpr and Vpu. Additionally, the last group of transcripts, the unspliced mRNAs 
are used for translation of the Gag-Pol polyprotein and as new genome for progeny virions. This 
complex and strongly regulated gene expression pattern is significantly regulated by the two proteins 
Tat and Rev. Tat enhances transcription by binding to a regulatory RNA element called TAR and 
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recruits elongation factors to the transcription complex resulting in strong enhancement of 
transcription. The viral protein Rev, which role is described in detail in C.1.6, plays an essential role 
in mediating the cascade-like gene expression [22]–[24]. Among others, HIV Gag that was mainly 
used to analyze the influence on codon usage on viral gene expression in this work, depends on the 
Rev-mediated mRNA export.  
C.1.5 The HIV-1 Gag Polyprotein 
The Gag (group-specific antigen) polyprotein of HIV-1 is the main structural protein of the virus and 
is translated from an unspliced 9 kb transcript. Gag plays also an important role in the immune 
response against HIV, since the initial HIV-specific immune response is directed against Tat, Rev and 
Gag. Because the regulatory and accessory proteins show a higher mutation rate, the immune 
response against Gag plays a key role to fight the virus.[25], [26]. Intensive research has shown the 
importance of Gag for the viral life cycle. Initially assumed as a simple scaffold protein, Gag 
meanwhile is known to specifically recognize genomic RNA as well as viral and cellular proteins [27]. 
Furthermore, Gag is necessary and sufficient for budding of HIV from the host's plasma membrane 
[28]. Therefore, Gag has to package two copies of viral genomic RNA per particle [29] and interact 
with cellular trafficking proteins to hijack the endosomal-sorting complexes required for transport 
(ESCRT) system [30]–[32].  
 
Figure C-5: Schematic overview of the budding process of HIV-1 mediated by Gag (from [33]) 
Gag proteins move towards the plasma membrane, interact with each other and induce extrusion of the lipid bilayer, 
followed by the membrane fusion to pinch-off the virion. Lastly, proteolytic processing by the viral protease leads to the 
maturation of the viral particle [33], [34].  
Structurally, Gag can be divided into four major domains: The matrix, capsid, nucleocapsid and link 
protein, each playing a different role during the viral life cycle.  
The matrix protein consists of 128 amino acids and plays an essential role for plasma membrane 
targeting and viral assembly. For both processes, an N-terminal myristoylation at Gly-2 plays a key 
role [35], [36], since it allows the binding of Gag to cholesterol- and sphingomyelin-rich micro 
domains within the plasma membrane [37].  
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The capsid protein is responsible for forming the core of the virus and can be divided into a C-terminal 
and N-terminal domain (CTD and NTD), joined by a flexible linker [38], [39] and a hexameric protein 
lattice is produced by CTD interaction[40]. Since formation of the mature and immature virus is 
strongly dependent on the CA-CA interaction, inhibitors targeting different sites of the capsid protein 
can have severe effects on viral replication, making CA an interesting target for an antiviral therapy 
[27], [41].   
The nucleocapsid protein (NC) has several functions despite being one of the smallest parts of Gag 
with only 55 amino acids. During viral maturation and assembly, NC is involved in Gag-Gag interaction 
as well as in the recognition of the nucleic acid [27]. An important feature are two zinc finger motifs 
which are separated by a functionally important basic domain [42]. Furthermore, NC acts as an RNA 
chaperone and supports reverse transcription as well as the integration in the host's genome [10].  
The last component of Gag is the 52 amino acid long link protein (p6). It gets translated as two 
different forms, the in-frame Gag p6 and the -1 frameshifted Gag–Pol p6*. It plays an important role 
for the release of new virions from the plasma membrane because of the so-called late domain of 
HIV, a sequence which seems to be responsible for the separation of the viral envelope and the 
cellular plasma membrane [43]–[46]. As mentioned above, the expression of Gag is strongly 
dependent on the accessory protein Rev and its interaction with a conserved sequence called the 
Rev-responsive element. 
C.1.6 The role of the Rev protein and the Rev-responsive element in the life 
cycle of HIV 
The regulatory protein Rev is a 13-kDa phosphoprotein which allows the export of unspliced and 
incompletely spliced viral mRNAs. Rev consists of 116 amino acids which are encoded by two exons 
and consists of several distinct domains 
[10], [47]–[50]. At the N-terminus an 
arginine rich motif functions as a nuclear 
localization sequence (NLS) [51], [52]. The 
interaction with a conserved RNA 
secondary structure called Rev-
responsive element (RRE), which is 
present in all unspliced and incompletely 
spliced HI-viral mRNAs, is mediated by a 
arginine rich domain between amino acid 
35 and 50 [10], [52], [53]. The RRE is a ∼ 
350 nucleotide long, highly structured 
element inside of the env RNA. It forms a 
conserved secondary structure with five 
stems around a central loop, according to 
Figure C-6: Five stem model of the Rev-responsive element from [34]:  
Rev binding sides are shown in grey 
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the original model. Later, a 4-stem model suggested that stem loop III and IV form a hybrid III/IV stem 
loop together with the intervening loop region [54]–[56]. Initially Rev binds to the IIB site, followed 
by a multimerization of Rev by five additional molecules. The bi-directional transport is mediated by 
a nuclear localization signal (NLS) and a distinct nuclear export signal (NES). The NLS overlaps with 
the RNA-binding domain, while a leucine-rich sequence acts as the NES, allowing the interaction with 
cellular mRNA export proteins [47], [57]. Especially the amino acids between position 73 and 84 are 
essential for the Rev-mediated nuclear export, since they mediate the interaction with exportin 1, 
also known as CRM1 (chromosomal maintenance gene 1) which binds to the GTP-loaded form of the 
Ran protein. Thereby, the mRNA-Rev-protein-Crm1-Ran-GTP complex is exported out of the nucleus 
through the nuclear pores. By hydrolyzation of GTP, Crm1 and Ran disengage themselves from the 
export complex and Rev dissociates from the mRNA which now gets translated. By this mechanism 
HIV ensures that all viral gene products can get translated in a highly regulated way (see Figure C-7). 
 
Figure C-7: Role of Rev in the HIV-1 life cycle (from [58]) 
HIV transcripts can be classified into unspliced, incompletely spliced and fully spliced mRNAs. At the beginning of infection, 
in the absence of Rev, only fully spliced mRNAs can be exported out of the nucleus. From those mRNAs, Tat, Nef and Rev get 
translated. Unspliced and incompletely spliced mRNAs are retained inside of the nucleus until Rev migrates back, binds to a 
secondary structure known as Rev-responsive element, which is present in all variants of unspliced and incompletely spliced 
transcripts and mediates the export of those mRNAs. For this, Rev interacts with exportin 1, also known as CRM-1 which 
mediates the export through the nuclear pore [58].  
The fully spliced transcripts that get exported even in the absence of Rev use cellular proteins for the 
mRNA export. The correct transport of all different classes of RNA in general is a highly regulated 
process and is described in the following chapter. 
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C.1.7 Usage of a subgenomic gag reporter system to analyze the effects of 
codon adaptation on viral gene expression  
To analyze the effects of altered codon usage on gag expression independently of other processes in 
the life cycle of HIV like infectivity, uncoating, reverse transcription or budding, a simplified gag 
reporter system was used, which was established in previous studies of our group. For this, the fact 
was used that HIV-1’s late gene expression depends on cis-acting elements as well as the interaction 
of Rev with the RRE. For mimicking of this situation the 5’ UTR of HIV-1 carrying the highly functional 
major splice donor SD1 was fused upstream and a fragment known to carry the RRE was fused down-
stream to the gag-encoding open reading frame. Adapting the gag gene to human codon usage 
resulted in constitutive nuclear export allowing high levels of Gag expression independently of the 
Rev/Rev-responsive element system because of the modification of intragenic regulatory elements 
[59]. Later, it was shown that it is possible to transfer this reporter system also to other report genes, 
like the green fluorescent protein (GFP). Adapting the open reading frame of GFP to HIV-1’s codon 
usage was sufficient to turn this hivGFP RNA into a quasi-lentiviral message following the rules of late 
lentiviral gene expression. Again, cis-active elements which are known to influence HIV-1gene 
expression, like the 5’UTR as well as the RRE were added either upstream (5’UTR) or downstream 
(RRE) of the open reading frame [60]. This principle was used in several studies of our group and also 
in this thesis, in order to analyze the influence of partial codon adaptation on viral gene expression.  
C.1.8 The role of the Tat protein in the transcription of viral genes by the 
cellular RNA polymerase II 
The transactivator of transcription (Tat) plays a central role in the life cycle of HIV, since it mediates 
a more than hundred enhanced transcription of viral genes from the LTR promoter by binding to the 
TAR (transactivation response) element. The TAR element is a secondary structure which is built 
across the first 59 nucleotides and is present at the 5’ part of all viral mRNA species. The binding of 
Tat is followed by the recruitment of the positive transcription elongation complex (P-TEFb), which 
consists of CDK9 and Cyclin T1. CDK9 then phosphorylates the carboxyl terminal domain of RNAP II. 
Transcription by RNAP II is a highly complex process from initiation to termination. Transcriptional 
initiation requires the assembly of the preinitiation complex (PIC), composed of the general 
transcription factors (GTFs) TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH; the Mediator complex; and 
RNAP II with an unphosphorylated carboxy terminal domain (CTD). But, throughout the process of 
transcription, the CTD becomes highly phosphorylated which enhances the transcriptional activity 
[61]–[63]. This process is mediated by the Tat protein in the gene expression of HIV-1.  
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 RNA export from the nucleus to the cytoplasm 
As already mentioned above, the fully spliced transcripts are exported without the help of viral 
proteins like Rev. Those mRNAs are transported by the same mechanisms that are responsible for 
the export of cellular mRNAs. In general, for different RNA species that get exported out of the 
nucleus through the nuclear pore, different export pathways are used. Small RNAs, like tRNAs and 
micro RNAs get exported by relatively simple export pathways. Their transport is mediated by a direct 
binding to their respective export receptors. For example, the export of tRNAs is mediated by the 
export receptor exportin-t, a member of the karyopherin superfamily, which binds directly to tRNAs 
in a RanGTP-dependent manner. After transport of the tRNA-exportin-t-RanGTP complex to the 
cytoplasm, RanGAP stimulates GTP hydrolysis on Ran, inducing the release of the tRNA cargo from 
its receptor (see below) [64]–[66]. Large RNAs, like rRNAs and mRNAs build quite complex 
ribonucleoprotein (RNP) particles, including specific adaptor proteins to the given export factors [65].  
 
Figure C-8: Schematic illustration of different RNA export pathways (from [65] 
The major routes of RNA export pathways are shown. Those include tRNAs, microRNAs (miRNAs), small nuclear (sn)RNAs, 
messenger RNAs (mRNAs) and ribosomal RNAs (rRNAs). The primary transcripts are shown at the top as well as the 
molecules after processing, maturation and assembly with export factors (export adaptors are shown in blue, export 
receptors are shown in yellow). For the mRNA pathway, metazoan and yeast proteins are listed and additional adaptor 
proteins and RNA binding factors (orange ovals) are depicted.  
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The precursor mRNA molecules undergo different processing steps like capping, splicing and 
cleavage/polyadenylation at the 3' end. For this, the mRNA associates with a variety of proteins to 
form a ribonucleoprotein particle (mRNP). Furthermore, an interaction with nuclear export factors 
also occurs already during 
transcription and processing, 
which ensures that only 
completely functional transcripts 
are provided to the translational 
machinery [67]. In principle the 
processes during mRNA export are 
as follows. Transcription of pre-
mRNA molecules is carried out by 
RNA-polymerase II followed by an 
immediate assembly into RNPs, 
containing several heterogeneous 
nuclear ribonucleoproteins 
(hnRNPs) and splicing 
commitment factors. Those 
mRNAs remain inside the nucleus until the completion of splicing, when commitment factors are 
released and the nuclear mRNA export factors Tap and p15 are recruited to the mature mRNA. 
Subsequently, the RNP docks at the nuclear pore complex (NPC) and enters the cytoplasm. 
Nonshuttling hnRNPs have to be released at this point for example by the RNA helicase Dbp5. After 
the nuclear export, binding of cytoplasmic RNA binding protein occurs followed by translation of the 
mRNA. The shuttling hnRNPs like hnRNP A1 and nuclear mRNA export factors, including Tap and p15, 
are released and recycled to the nucleus [68].  
 The genetic code and its role in protein biosynthesis 
The genetic code has a central place in biology, since it defines the rules to translate the 4-letter 
alphabet of nucleic acids into amino acid sequences, the 20-letter alphabet of proteins [69]. This 
process, known as protein biosynthesis, starts already in the nucleus with the transcription of DNA 
into a messenger RNA (mRNA). After the export of the mRNA into the cytoplasm (see above), the 
given nucleotide sequence gets translated according to the genetic code into an amino acid 
sequence, generating new proteins. These processes underlie complex and highly regulated 
mechanisms, themselves, like transcription initiation, elongation and termination, as well as post-
transcriptional modification. This is also true for nuclear export processes or translational processes 
like initiation, elongation, transcription and post-translational modifications. Those mechanisms 
have been studied intensively over the years and were summarized in different excellent reviews 
Figure C-9: Export of eukaryotic mRNA from the nucleus (from [61]) 
Processes and proteins involved in the nuclear export of mRNAs. Letters A-C 
stand for hnRNPs, S stands for splicing commitment factors. Explanation given 
in text.  
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[70]–[74]. A simplified schematic illustration of the translation of a DNA sequence into an amino acid 
sequence is shown in Figure C-10.  
 
Figure C-10: Schematic and simplified overview of different processes involved in protein biosynthesis (from [69]) 
(1) Unwinding of the DNA double helix to allow transcription of the desired sequence into an mRNA molecule (2) which 
gets transported through the nuclear pore into the cytoplasm (3). After that, the mRNA attaches to the ribosome where 
transfer RNAs (tRNAs), each carrying a specific amino acid, interact with the mRNA trough the tRNA’s anticodon (4). 
Elongation occurs and a growing peptide chain is generated (5) [69]. 
The genetic code is universal, which means that it is used by all creatures and plays a central role in 
the processes shown above, since it determines which amino acid sequence gets translated from the 
codons of the mRNA molecule. After the double helical structure of DNA was deciphered by Watson 
and Crick in 1953 [75] fundamental findings regarding the genetic code were done during the 1960s. 
In 1961 Crick and Brenner performed a historic experiment to demonstrate that the genetic code is 
made up of a series of three base pairs codons by using mutants in the rII locus of T4 phage [76]. 
Later, based on the finding that poly-uracil RNA incorporated only phenylalanine [77], Nirenberg was 
able to decipher the genetic code [78]. Since the genetic code acts as a fundamental feature all over 
in biology, it was and still is subject of intensive research that results in four key points, which should 
always be remembered about the genetic code. Firstly, the genetic code is non-overlapping. That 
means, consecutive amino acids are determined by consecutive codons. In an overlapping code, 
consecutive amino acids would be encoded by codons that share some bases. Secondly, an amino 
acid is always encoded by three bases, which are termed codons. Thirdly, the code is read from a 
defined starting point to an end point, which determines the coding region. And fourthly, the code is 
degenerated. That means some amino acids are encoded by more than one codon. This degeneracy 
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is mediated by a loose kind of base pairing at one end of the codon and anticodon, called wobble 
position [79]. So, some amino acids can be transported to the ribosome by several tRNAs with 
different anticodons, whereas for certain other amino acids this can only be done by one specific 
tRNA. Figure C-11 shows how 61 codons encode the 20 amino acids and three stop codons.  
 
Figure C-11: The genetic code (from [80]) 
Shown are the 20 amino acids and their chemical features (indicated by different colors) and how they are encoded by 
the different codons.  
The degeneracy of the genetic code is also the basic principle for codon bias and codon optimization, 
two points that play a central role in this thesis and will be explained in the following chapters.  
 Codon usage and codon usage bias 
The degeneracy of the genetic code allows the usage of different codons for the same amino acid. 
Those codons are called synonymous codons and contrary to the first intuition those codons are not 
used in an equal frequency, but some codons are preferred. This phenomenon is known as codon 
usage bias and varies between and among species [81]. As explanations for the non-random usage 
of different codons a combination of mutation, selection and random drift is proposed [82]. In this 
model a balance between those forces favors specific, superior codons. That means that a mutation 
in an unpreferred codon could result in the generation of a preferred one when this allows a more 
efficient way of gene expression [83]–[86]. Furthermore, highly expressed genes show in general a 
stronger bias in synonymous codon usage [87]–[89]. As explanation for this phenomenon, one of the 
most intensively supported hypotheses over the years was translational selection. This theory is 
generally explained by better fitting codons for the most abundant isoaccepting tRNAs [90]–[92]. A 
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fact, which might be true for prokaryotes, where frequently used codons correlate with abundant 
cognate isoacceptor transfer RNAs [93].But especially for eukaryotes a variety of factors like GC-
content, recombination rate, RNA stability, codon position and gene length can also influence codon 
usage bias [83], [94]–[98]. Therefore, translational efficiency by itself is not sufficient to account for 
effects of synonymous codon usage in higher organism. Especially the perception of the influence of 
synonymous codons on RNA level rose over the last years. Chen et al. quantified the impact of 
synonymous codons on mRNA level by analyzing over 3556 variants of a heterologous gene encoding 
the green fluorescent protein (GFP) and 523 synonymous variants of the endogenous gene TDH3 in 
yeast. They could show a positive correlation between mRNA levels and codon usage bias, which 
points to a direct effect of synonymous mutations on transcript concentration, most likely by 
influencing mRNA degradation rate [99]. Further studies point into the same direction. Kholiswa et 
al showed in 2008 that transfection of Jurkat cells with codon-optimized gag mRNAs led to a small 
increase in Gag production, whereas transfection of optimized DNA resulted in a very large 
enhancement of expression, indicating a higher ranking role of mRNA levels [100]. Furthermore, also 
our group could show that codon-usage-mediated inhibition of HIV-1 gag expression in mammalian 
cells occurs independently of translation [101].  
 Codon optimization and deoptimization  
The fact that amino acids can be decoded in most cases by more than one codon facilitates the option 
to change codon choice as a molecular biological tool in form of codon optimization and 
deoptimization. Codon optimization and deoptimization describes the possibility to change the 
natural codon usage in two different directions. So, it is possible to introduce synonymous mutations 
in a coding region that do not affect the amino acid sequence of a protein but substitute specific 
nucleotides so that either better or worse fitting codons are generated. For this, a robust method 
had to be used to quantify codon usage bias. For this problem, different methods exist [102] and are 
favored by different groups. For the analysis in this thesis, the codon adaptation index (CAI) [103] 
was predominantly used, which is defined as the geometric mean of the relative adaptiveness values 
(w) of individual codons. The relative adaptiveness (w) of a codon is the ratio of the observed 
frequency of that codon to the frequency of the most abundant codon for the same amino acid. The 
most abundant codon is calculated for a reference set of highly expressed genes, such as ribosomal 
protein genes. Thus, 𝑊 =
𝑋𝑖𝑗
𝑋𝑖𝑚𝑎𝑥
  where Xij is the observed frequency of the ith codon for the jth amino 
acid and Ximax is the maximal X value for codons for the same amino acid [83]. The probably widest 
application for codon optimization is in heterologous gene expression, a well-established method to 
produce recombinant protein products like drugs, industrial enzymes or biofuels in foreign organisms 
more efficiently [104]–[108]. On the other hand, it is also possible to worsen the codon usage by 
using synonymous mutations. As an example, it was already shown that replacement of optimal 
codons in viral genomes can lead to attenuated viruses by influencing different features like 
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dinucleotide frequency, GC-content or codon pairs [109]–[111]. In this thesis an optimization of HIV-
gag was performed in order to analyze the effects of altered codon usage on viral gene expression 
and the thereby mediated Rev-dependency/independency as already described in several earlier 
studies of our group [59], [60], [112]–[114]. Further The prerequisite to do this is the different 
nucleotide composition of HIV compared to its human host. 
 Nucleotide composition of HIV 
Despite the necessity of HIV to use the host’s translational machinery for viral gene expression, the 
virus exhibits an A-rich nucleotide composition with 36.2% A, 23.9% G, 22.2% U and 17.6% C, which 
differs clearly from the GC-rich coding regions of humans, where e.g. the GC content of isochores can 
be up to 60% [115]–[118]. The deviating codon usage is not exclusive for HIV, since also other viruses 
show an A-rich nucleotide composition or a differing codon usage compared to their hosts in general 
[119], [120]. From an evolutionary point that raises the question whether or how far the viruses 
benefit from different codon choice, because after all they rely on cellular processes like transcription 
or translation and therefore need to take over cellular functions and direct them towards the efficient 
production of new viruses [121]. The fast adaptation of HIV-1 epitopes to specific human MHC-I 
molecules validates the importance of viral evolution and adjustment to their hosts [122]. Therefore, 
there must be reasons why the deviating nucleotide composition of HIV-1 has evolved and seems to 
be maintained. In general, regarding this question, a model consisting of a combination of mutational 
activity and/or evolutionary selection is often favored [123]. Mutational activity could be caused 
either by the enzymatic properties of the error prone reverse transcriptase or by the cellular editing 
activities of the APOBEC enzyme (apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like) 
[124]. The first point can be explained by a biased guanine (G) to adenine (A) transition induced by 
an imbalanced dNTP pool during reverse transcription [125]. In addition it was shown that cytidine 
deamination by the restriction factor APOBEC3G/3F also contributes to the hypermutation [126]. 
APOBEC describes an evolutionary conserved class of enzymes catalyzing C-to-U editing by 
deamination of cytidine. In this reaction, a coordinated zinc ion in an enzyme active site acts as a 
Lewis acid to activate a water molecule for hydrolytic, nucleophilic attack of the amide group at the 
C4 position of cytidine and a conserved glutamic acid acts as a proton shuttle to convert a cytidine 
base to a uridine with an ammonium leaving group [127]. Despite all these facts, the question 
remains what effects an altered codon usage would have on viral gene expression and what 
molecular mechanisms are involved. To gain insight into this question was a central point of this 
thesis. 
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  Objective  
The question how an altered codon usage affects viral replication has been addressed in different 
studies for different viruses, but most of them focused on the influence of synonymous codons on 
viral replication [109]–[111], [128]. All of these studies provide important findings in the field of 
synonymous codon usage but rely on the complex interplay of several processes of viral replication 
but not gene expression per se. To address this direct influence of codon adaptation on gene 
expression, a simplified system of subgenomic gag reporter variants with varying codon-
adapted(humanized) parts should be used to study the effects on gene expression independently 
from other biological processes of the replication cycle of HIV. For this, subgenomic gag reporter 
genes with systematically enlarged humanized parts under the control of a heterologous CMV 
promoter should be generated. In previous studies, our group already established this subgenomic 
reporter system in order to analyze the effects of codon usage on HIV gag gene expression [59]. We 
could show that a complete humanization of HIV gag led to a Rev-independent and constitutive 
export of gag by elimination of cis-acting sequences [59]. Furthermore, humanization significantly 
Figure C-12: Schematic illustration of the objective of this thesis: 
The Impact of partial humanization (wtGag vs. huGag) should be investigated on different biological stages. Quantification 
of mRNA and protein levels should be performed as well as experiments analyzing the differences in transcription 
efficiency, mRNA stability, export pathways and effects on translational processes. 
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increased gag expression in dependency of the ratio of native and optimized codons [101]. To analyze 
positional and additive effects of codon optimization in a more detailed and systematic way, the 
subgenomic reporter system should be used in this work to analyze the effects of partially humanized 
variants. Therefore, the expression of the partially humanized variants should be analyzed on protein 
as well as mRNA levels, either by ELISA or by quantitative real time PCR. To get insight into the 
underlying molecular mechanisms, different molecular biological analyses regarding mRNA half-life, 
or transcriptional efficiency should be performed, as well as the analysis of potential alternative 
splicing effects. To address the question to what extent the results would be transferable to other 
genes, egfp should be used as an additional reporter gene. For this, a quasi-lentiviral GFP reporter 
system should be used, which our group established in a previous work [59], [60]. Taken together, 
the aim of this work should be to address the impact of humanization on the gene expression of HIV-
1 in the context of various biological processes, as shown in Figure C-12. 
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D Material and methods 
 Cell lines 
D.1.1 Prokaryotic cell lines 
Table D-1: Overview of prokaryotic strains  
D.1.2 Eukaryotic cell lines  
Table D-2: Overview of eukaryotic cell lines used 
 Nucleic acids  
D.2.1 Oligonucleotides 
Table D-3: Overview of oligonucleotides used 
Primer name Sequence Usage 
Gag_c_wt_hu rev CTGCAGTGTACTAGTAGTTCCTGCTATGTCACTTC cloning of gag variants 
Gag_c_wt_hu fwd CAGGAACTACTAGTACACTGCAGGAACAGATCG cloning of gag variants 
Gag_d_hu_wt rev GGCCCTGCAGTTCTTGGCAATGTGGC cloning of gag variants 
Gag_d_hu_wt fwd CCAAGAACTGCAGGGCCCCTAGGAAAAAGGG cloning of gag variants 
Gag_c_wt_hiv rev CTCTTGCAGTGTACTAGTAGTTCCTGCTATGTCACTTC cloning of gag variants 
Gag_d_hiv_wt fwd GCAAAGAACTGTAGGGCCCCTAGGAAAAAGGG cloning of gag variants 
Gag_c_wt_hiv fwd GGAACTACTAGTACACTGCAAGAGCAGATAGGAT cloning of gag variants 
Gag_d_hiv_wt rev GGGCCCTACAGTTCTTTGCTATGTGCCC cloning of gag variants 
Gag_b_wt_hu rev GCACCATTTGCCCCTGGAGGTTCTG cloning of gag variants 
Gag_b_wt_hu fwd CCAGGGGCAAATGGTGCATCAGGCCATC cloning of gag variants 
Strain Genotype 
DH5α F- supE44 ΔlacU169 (φ80 lacZΔM15) hsdR1 recA1 endA1 gyrA96 thi-  
1 relA1 [129] 
DH10B 
F- mcrA Δ(mrr-hsdRMS-mcrBC) Φ80dlacZΔM15 ΔlacX74 endA1 recA1 deoR  
Δ(ara,leu)7697 araD139 galU galK nupG rpsL λ- [130] 
  
Cell line Description 
HEK293T 
Ad5-transformed human embryonic kidney cell line [131], expressing the “SV40 large 
T-antigen” [132] 
 
HeLa Human epithelial cell line (derived from cervix carcinoma) 
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Gag_b_wt_hiv fwd CAGGGGCAAATGGTACACCAGGCAATATCAC cloning of gag variants 
Gag_f_hu_wt rev GATCTTTACTGGCTGCTAGGATCGC cloning of gag variants 
Gag_f_hu_wt fwd CCTAGCAGCCAGTAAAGATCTTCAGACCTGGAGGAG cloning of gag variants 
Gag_f_hiv_wt rev GTCTGAAGATCTTTACTGCTTGGATCGCTTC cloning of gag variants 
Gag_f_hiv_wt fwd CAAGCAGTCAGTAAAGATCTTCAGACCTGGAGGAG cloning of gag variants 
Gag_e_hu_wt rev CCTAAAAAATTGGCCTGCCGCTCG cloning of gag variants 
Gag_e_hu_wt fwd GAGCGGCAGGCCAATTTTTTAGGGAAGATCTGGCCTTCC cloning of gag variants 
Gag_e_hiv_wt rev TCTGAAGAAAATTTGCCTGTCTCTCTGTGCA cloning of gag variants 
Gag_e_hiv_wt fwd CACAGAGAGACAGGCAAATTTTTTAGGGAAGATCTGGCCTTCC cloning of gag variants 
Gag_a_wt_hu rev GGCTCCCATCTCTCTCCTTCTAGCCTCCG cloning of gag variants 
Gag_a_wt_hiv rev CTCTTGCTCCCATCTCTCTCCTTCTAGCCTCCG cloning of gag variants 
Gag_a_wt_hu fwd GAAGGAGAGAGATGGGAGCCAGAGCCTC cloning of gag variants 
Gag_a_wt_hiv fwd GGAGAGAGATGGGAGCAAGAGCAAGC cloning of gag variants 
Gag_b_wt_hiv rev GGTGTACCATTTGCCCCTGGAGGTTCTG cloning of gag variants 
Gag_c2_hu_wt fwd CCACCAGCACCCTTCAGGAACAAATAGGATGG cloning of gag variants 
Gag_c2_hu_wt rev CTGAAGGGTGCTGGTGGTGCCGG cloning of gag variants 
ß-actin-Exon3-fwd CACTGTGCCCATCTACGAGG cloning of gag variants 
ß-actin-Exon3-rev CTCTTGCTCGAAGTCCAGGG cloning of gag variants 
Gag_d_wt_hu rev CTGGGGGCTCTGCAATTTTTGGCTATGTGCCCTT cloning of gag variants 
Gag_d_wt_hu_fwd CAAAAATTGCAGAGCCCCCAGAAAGAAAGG cloning of gag variants 
Gag_e_wt_hu_rev CCAGGAAGTTAGCCTGTCTCTCAGTACAATCTTT cloning of gag variants 
Gag_e_wt_hu_fwd AGAGACAGGCTAACTTCCTGGGCAAGATCTG cloning of gag variants 
TS - A Erw1 (A5-A6) 
Rev 
TGCTGGGCCTTTTTCTTACTTTTGTTTTGCTCTTCCTCTATC cloning of gag variants 
TS - A Erw1 (A5-A6) 
For 
AAAACAAAAGTAAGAAAAAGGCCCAGCAGGCTGC cloning of gag variants 
TS - A Erw2 (A4-A6) 
Rev 
TGCACACAATAGAGGACTGCTATTGTATTATATAATGATC cloning of gag variants 
TS - A Erw2 (A4-A6) 
For 
GCAGTCCTCTATTGTGTGCACCAGCGGATCG cloning of gag variants 
TS - A Erw3 (A3-A6) 
Rev 
GCTGGCCCAGTATTTGTCTACAGCCTTCTGATGTC cloning of gag variants 
TS - A Erw3 (A3-A6) 
Fwd 
GTAGACAAATACTGGGCCAGCTGCAG cloning of gag variants 
TS - A Erw4 (A2-A6) 
Rev 
CTGGCCCACACGATATGTTTTAGTTTATATTGTTTCTTTCCCCCTGG cloning of gag variants 
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TS - A Erw4 (A2-A6) 
Fwd 
CTAAAACATATCGTGTGGGCCAGC cloning of gag variants 
TS - A Erw5 (A2-A6) 
Rev 
GACAGCACCGACGCTCTCGCACC cloning of gag variants 
TS - A Erw5 (A2-A6) 
Fwd 
GAGCGTCGGTGCTGTCTGGCGGC cloning of gag variants 
TS - A Erw6* (A1-A2) 
Rev 
GCTTAATACAGAGGCTCTGGCTCCC cloning of gag variants 
TS - A Erw6* (A1-A2) 
Fwd 
AGCCAGAGCCTCTGTATTAAGCGGGGGAGAATTAGATAAATGG cloning of gag variants 
TS-BsmBI-MK3-
vorne_fwd (105) 
GAGAGAGAGACGTGGGTGCGAGAGCG cloning of gag variants 
TS-BsmBI-MK3-
vorne_rev (105) 
CACCCACGTCTCTCTCTCTCCTTCTAGCCTCC cloning of gag variants 
TS-BsmBI-MK1_fwd  
(hinten_285) 
GACAAATACCGTCTCTGGGCCAGCTGCAG cloning of gag variants 
TS-BsmBI-MK1_rev  
(hinten_285) 
GCCCAGAGACGGTATTTGTCTACAGCCTTCTGATGT cloning of gag variants 
TS-BsmBI-MK1_fwd  
(vorne_225) 
AGCTAGAGAGACGACGATTCGCAGTTAATCCTGGC cloning of gag variants 
TS-BsmBI-MK1_rev  
(vorne_225) 
CGAATCGTCGTCTCTCTAGCTCCCTGCTTGCC cloning of gag variants 
TS-BsmBI-MK2_rev  
(hinten_225) 
CTTTCCAGGAGACGGCTCTCTGCTGGCCCAC cloning of gag variants 
TS-BsmBI-MK2_fwd  
(hinten_225) 
AGAGAGCCGTCTCCTGGAAAGATTCGCCGTGAAC cloning of gag variants 
TS-BsmBI-MK2_rev  
(vorne_165) 
TGGCCGTCTCCTTAACCGAATTTTTTCCCATTTATCTAATTCTCCC cloning of gag variants 
TS-BsmBI-MK2_fwd  
(vorne_165) 
CGGTTAAGGAGACGGCCAGGGGGAAAGAAACAATATAAACTAAA
AC 
cloning of gag variants 
TS-BsmBI-MK3_rev  
(hinten_165) 
CGCAGTGAGACGCTGATCTTCTCCCACTTGTCC cloning of gag variants 
TS-BsmBI-MK3_fwd  
(hinten_165) 
ATCAGCGTCTCACTGCGGCCTGGC cloning of gag variants 
pCMV-LTR_NL4-3 fwd GTACACGCGTTGGAAGGGCTAATTTGGTCCC cloning of gag variants 
pCMV-LTR_NL4-3 rev GCCGAGTCCTGCGTC cloning of gag variants 
pCMV-LTR_NL4-3 fwd 
(PCR1b) 
GACGCAGGACTCGGC cloning of gag variants 
TS-wt15-
90_PCR1a_Rev 
CTTAATACCGAGGCTCTGGCTCCCATC cloning of gag variants 
TS-wt15-
90_PCR1b_Fwd 
AGCCAGAGCCTCGGTATTAAGCGGGGGAG cloning of gag variants 
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TS-wt30-
90_PCR1a_Rev 
CTAATTCTCCGCCAGACAGCACAGAGG cloning of gag variants 
TS-wt30-
90_PCR1b_Fwd 
GCTGTCTGGCGGAGAATTAGATAAATGGGAAAAAATTCGGTTAA
GG 
cloning of gag variants 
TS-wt45-
90_PCR1a_Rev 
GAATTTTTTCCCACTTGTCCAGCTCGCCG cloning of gag variants 
TS-wt45-
90_PCR1b_Fwd 
GAGCTGGACAAGTGGGAAAAAATTCGGTTAAGGCCAG cloning of gag variants 
TS-wt60-
90_PCR1a_Rev 
CCCTGGCCTTAATCTGATCTTCTCCCACTTGTCC cloning of gag variants 
TS-wt60-
90_PCR1b_Fwd 
GAGAAGATCAGATTAAGGCCAGGGGGAAAGAAAC cloning of gag variants 
TS-wt75-
90_PCR1a_Rev 
GTTTCTTGCCGCCAGGCCG cloning of gag variants 
TS-wt75-
90_PCR1b_Fwd 
GCCTGGCGGCAAGAAACAATATAAACTGAAGCACATCGTG cloning of gag variants 
TS-wt30-
75_PCR1a_Rev 
CTAATTCTCCGCCAGACAGCACAGAGG cloning of gag variants 
TS-wt30-
75_PCR1b_Fwd 
GCTGTCTGGCGGAGAATTAGATAAATGGGAAAAAATTCGGTTAA
GG 
cloning of gag variants 
TS-wt45-
60_PCR1a_Rev 
GAATTTTTTCCCACTTGTCCAGCTCGCCG cloning of gag variants 
TS-wt45-
60_PCR1b_Fwd 
GAGCTGGACAAGTGGGAAAAAATTCGGTTAAGGCCTG cloning of gag variants 
TS-wt15-
30_PCR1a_Rev 
CTTAATACCGAGGCTCTGGCTCCCATC cloning of gag variants 
TS-wt15-
30_PCR1b_Fwd 
AGCCAGAGCCTCGGTATTAAGCGGGGGC cloning of gag variants 
TS-wt30-
45_PCR1a_Rev 
CTAATTCTCCGCCAGACAGCACAGAGG cloning of gag variants 
TS-wt30-
45_PCR1b_Fwd 
GCTGTCTGGCGGAGAATTAGATAAATGGGAGAAGATCAGAC cloning of gag variants 
TS-wt60-
75_PCR1a_Rev 
CCCTGGCCTTAATCTGATCTTCTCCCACTTGTCC cloning of gag variants 
TS-wt60-
75_PCR1b_Fwd 
GAGAAGATCAGATTAAGGCCAGGGGGCAAG cloning of gag variants 
hu60-75_PCR1a_Rev TTTTAGTTTATATTGTTTCTTGCCGCCAGGCC cloning of gag variants 
hu60-75_PCR1b_Fwd 
CCTGGCGGCAAGAAACAATATAAACTAAAACATATAGTATGGGCA
AGC 
cloning of gag variants 
hu60-90_PCR1a_Rev CCATACTATATGTTTCAGCTTGTACTGCTTCTTGC cloning of gag variants 
hu60-90_PCR1b_Fwd GCAGTACAAGCTGAAACATATAGTATGGGCAAGCAGG cloning of gag variants 
fwd_hu_GFP_FranziW GACCTACGGCGTGCAATGCTTCAGCCGCTACCC cloning of egfp variants 
 Material and methods 
- 29 - 
 
rev_hu_GFP_FranziW CATTGCACGCCGTAGGTCAGGGTGGTCACGAGGGTG cloning of egfp variants 
fwd_hiv_GFP_FranziW AGTAACAACATTAACATATGGAGTACAATGTTTTAGCAGATATC cloning of egfp variants 
rev_hiv_GFP_FranziW CTCCATATGTTAATGTTGTTACTAATGTTGGCCAGG cloning of egfp variants 
huE_rev_FranziW CACGGGTCCGTCACCTATTGGTGTATTTTG cloning of egfp variants 
huE_fwd_FranziW AATAGGTGACGGACCCGTGCTGCTGCC cloning of egfp variants 
huA_fwd_FranziW CCTGAAGTTCATCTGTACAACAGGAAAATTACCAGTACCC cloning of egfp variants 
huA_rev_FranziW CCTGTTGTACAGATGAACTTCAGGGTCAGCTTG cloning of egfp variants 
huAB_rev_FranziW TATTGTTCTCTCCTGGACGTAGCCTTC cloning of egfp variants 
huAB_fwd_FranziW 
CTACGTCCAGGAGAGAACAATATTTTTTAAAGACGACGGAAATTA
TAAAACAAGA 
cloning of egfp variants 
huABC_fwd_FranziW 
CAAGCTGGAGTACAATTATAATAGCCATAATGTATATATAATGGC
AGACAAAC 
cloning of egfp variants 
huABC_rev_FranziW CATTATGGCTATTATAATTGTACTCCAGCTTGTGCCC cloning of egfp variants 
huABCD_rev_FranziW CTGGTAATAATACTGGGCCGTCGCCGATGG cloning of egfp variants 
huABCD_fwd_FranziW GACGGCCCAGTATTATTACCAGACAATCATTATTTAAGCAC cloning of egfp variants 
huBCDE_fwd_FranziW AATTTATATGCACCACCGGCAAG cloning of egfp variants 
huBCDE_rev_FranziW 
GGTGGTGCATATAAATTTTAATGTTAATTTTCCATATGTTGCGTCA
CC 
cloning of egfp variants 
huCDE_rev_FranziW GATGGTGCGTTCTTGTACATATCCTTCTGGCATTG cloning of egfp variants 
huCDE_fwd_FranziW GGATATGTACAAGAACGCACCATCTTCTTCAAGGAC cloning of egfp variants 
huDE_fwd_FranziW GGACATAAATTAGAATATAACTACAACAGCCACAACGTC cloning of egfp variants 
huDE_rev_FranziW 
GTGGCTGTTGTAGTTATATTCTAATTTATGTCCTAATATATTTCCGT
CCTCTTTAAAG 
cloning of egfp variants 
TS-ATG-wtA-hueGFP-
PCR1a Rev 
GCTCACCATTTGCCCCTGGAGGTTCTG cloning of egfp variants 
TS-ATG-wtA-hueGFP-
PCR1b Fwd 
CAGGGGCAAATGGTGAGCAAGGGCGA cloning of egfp variants 
ATG-huA-hueGFP-1a 
Rev 
CACCATCTGGCCCTGCAGATTCTG cloning of egfp variants 
ATG-huA-hueGFP-1b 
Fwd 
GCAGGGCCAGATGGTGAGCAAGGGCGA cloning of egfp variants 
ATT-huA-hueGFP-
PCR1a Rev 
TCTGGCTCCAATCTCTCTCCTTCTAGCCTCC cloning of egfp variants 
ATT-huA-hueGFP-
PCR1b Fwd  
GGAGAGAGATTGGAGCCAGAGCCTCTG cloning of egfp variants 
ATT-wtA-hueGFP-1a 
Rev  
CGCACCAATCTCTCTCCTTCTAGCCTCC cloning of egfp variants 
ATT-wtA-hueGFP-1b 
Fwd 
GAAGGAGAGAGATTGGTGCGAGAGCGTC cloning of egfp variants 
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hu_Gag ohne ATG 
PCR1a Rev 
GCTCTGGCTCCAATCTCTCTCCTTCTAGCCTCC cloning of egfp variants 
hu_Gag ohne ATG 
PCR1b Fwd 
GAGAGAGATTGGAGCCAGAGCCTCTG cloning of egfp variants 
wt_Gag ohne ATG 
PCR1a Rev 
CTCGCACCAATCTCTCTCCTTCTAGCCTCC cloning of egfp variants 
wt_Gag ohne ATG 
PCR1b Fwd 
GGAGAGAGATTGGTGCGAGAGCGTC cloning of egfp variants 
Alec_wtA_eGFP_Fusio
n_FW 
GGGGCAAGCCACCATGGTGAGCAAGGGC cloning of egfp variants 
Alec_wtA_eGFP_Fusio
n_RV 
CATGGTGGCTTGCCCCTGGAGGTTCTG cloning of egfp variants 
Alec_huA_eGFP_Fus_F
W 
GGCCAGGCCACCATGGTGAGCAAGGGC cloning of egfp variants 
Alec_huA_eGFP_Fus_
RV 
CATGGTGGCCTGGCCCTGCAGATTCTG cloning of egfp variants 
TS-5'UTR-
wt_C_eGFP_FWD 
AGGGCCCCTATGGTGAGCAAGGGCGA cloning of egfp variants 
TS- Gag_A_ATT_1a 
Rev  
TCTGGCTCCAATCTCTCTCCTTCTAGCCTCC 
mutation of the gag start 
codon  
TS- Gag_A_ATT_1b 
Fwd 
GGAGAGAGATTGGAGCCAGAGCCTCTG 
mutation of the gag start 
codon  
TS- 
Gag_A_ATT_hueGFP 
1a Rev  
CTCACCATCTGGCCCTGCAGATTCTG 
mutation of the gag start 
codon  
TS- 
Gag_A_ATT_hueGFP 
1b Rev  
CAGGGCCAGATGGTGAGCAAGGGCGA 
mutation of the gag start 
codon  
TS-SD1_GT-AA (fwd) CGACTGAAGAGTACGCCAAAAATTTTGACTAGCG 
mutation of the splice 
donor SD1 
TS-SD1_GT-AA (Rev) CAAAATTTTTGGCGTACTCTTCAGTCGCCGCCCC 
mutation of the splice 
donor SD1 
TS_Rev_cloning_Fwd CCAGGGTACCCTCGAAGCTAGT 
cloning of Rev expression 
plasmid 
TS_Rev_cloning_Rev CTGCTCGAGCTGTGGCATTGAG 
cloning of Rev expression 
plasmid 
TS- NADH  1 
(mito)_fwd 
CCACATCTACCATCACCCTC 
analysis nuclear and 
cytoplasmic RNA fractions 
TS- NADH  1 
(mito)_rev 
CCTAGGAAGATTGTAGTGGTGAG 
analysis nuclear and 
cytoplasmic RNA fractions 
TS- U2 small nuclear 
1_fwd 
GCTAAGATCAAGTGTAGTATCTGTTC 
analysis nuclear and 
cytoplasmic RNA fractions 
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TS- U2 small nuclear 
1_rev 
GCACCGTTCCTGGAGG 
analysis nuclear and 
cytoplasmic RNA fractions 
TS_Rev_seq_1_Fwd CTACCCTGTCCACCCCTCTG sequencing primer 
TS_Rev_seq_2_Fwd CGGAGCTGAATGAAGCCATAC sequencing primer 
TS_Rev_seq_3_Fwd GAAAGGCGGACAGGTATCCG sequencing primer 
CMV-Seq CGCAAATGGGCGGTAGGCGTG sequencing primer 
TS-LTR Seq.1 (fwd) GCTGCTTCGCGATGTAC sequencing primer 
TS-LTR Seq.2 (fwd) GACGCAGGACTCGGC sequencing primer 
TS-LTR Seq.3 (rev) CAATTGTCCCTCATATCGCCTC sequencing primer 
TS-LTR Seq.4 (fwd) GATCTTCAGACCTGGAGGAG sequencing primer 
 
D.2.2 Plasmids 
Table D-4: Overview of plasmids used 
Plasmid Description 
pc-UTR-wtGag16-30-huGag-
RRE 
eukaryotic expression plasmid with CMV-promoter, partially humanized gag gene, 
from Alec Geßner (see [133]) 
pc-UTR-wtGag31-45-huGag-
RRE 
eukaryotic expression plasmid with CMV-promoter, partially humanized gag gene, 
from Alec Geßner (see [133]) 
pc-UTR-wtGag46-60-huGag-
RRE 
eukaryotic expression plasmid with CMV-promoter, partially humanized gag gene, 
from Alec Geßner (see [133]) 
pc-UTR-wtGag61-75-huGag-
RRE 
eukaryotic expression plasmid with CMV-promoter, partially humanized gag gene, 
from Alec Geßner (see [133]) 
pc-UTR-wtGag76-90-huGag-
RRE 
eukaryotic expression plasmid with CMV-promoter, partially humanized gag gene, 
from Alec Geßner (see [133]) 
pc-UTR-wtGag16-90-huGag-
RRE 
eukaryotic expression plasmid with CMV-promoter, partially humanized gag gene, 
from Alec Geßner (see [133]) 
pc-UTR-wtGag31-90-huGag-
RRE 
eukaryotic expression plasmid with CMV-promoter, partially humanized gag gene,  
from Alec Geßner (see [133]) 
pc-UTR-wtGag46-90-huGag-
RRE 
eukaryotic expression plasmid with CMV-promoter, partially humanized gag gene,  
from Alec Geßner (see [133]) 
pc-UTR-wtGag61-90-huGag-
RRE 
eukaryotic expression plasmid with CMV-promoter, partially humanized gag gene,  
from Alec Geßner (see [133]) 
pc-UTR-wtGag31-75-huGag-
RRE 
eukaryotic expression plasmid with CMV-promoter, partially humanized gag gene,  
from Alec Geßner (see [133]) 
pc-UTR-ATT-huA-huEGFP eukaryotic expression plasmid with CMV-promoter, gag 5'UTR, RRE first 423bp of  
humanized gag gene without start codon and humanized egfp gene from Alec 
Geßner (see [133])  
pc-UTR-ATT-wtA-huEGFP eukaryotic expression plasmid with CMV-promoter, gag 5'UTR, RRE first 423bp of  
wild-type HIV-1 gag gene without start codon and humanized egfp gene from Alec 
Geßner (see [133]) 
pc-UTR-wtGag-RRE eukaryotic expression plasmid with CMV-promoter, wild-type HIV-1 gag gene, from 
Nane Eiber (see [112]) 
pc-UTR-huGag-RRE eukaryotic expression plasmid with CMV-promoter, wild-type HIV-1 gag gene, from 
Nane Eiber (see [112]) 
pc-UTR-huABC-RRE eukaryotic expression plasmid with CMV-promoter, wild-type HIV-1 gag gene, from 
Nane Eiber (see [112]) 
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pcDNA3.1 eukaryotic expression plasmid  (Thermo Fisher, Waltham, USA - V79020) 
pcDNA3.1-Rev eukaryotic expression plasmid with HIV-1 rev gene (Wager Lab) 
pcDNA3.1-Tat eukaryotic expression plasmid with HIV-1 tat gene (Wagner Lab) 
 
D.2.3 Antibodies 
Table D-5:Overview of antibodies used 
 
D.2.3.1 Enzymes 
Table D-6: 
 
D.2.4 Commercial Kits 
Table D-7: 
Antibody Supplier/Specification 
M01-antibody (anti-p24) Polymun (AB006) 
37G12-antibody (anti-p24), 
biotinylated  
Polymun (AB005) 
Anti-DIG Antibody (from DIG 
Northern Starter Kit) 
Polyclonal sheep anti-digoxigenin, Fab-fragments, 
conjugated to alkaline phosphatase 
Primer Sequence 
Restriction endonucleases New England Biolabs 
Trypsin/EDTA Pan Biotech 
Phusion DNA-Polymerase  Finnzymes 
Calf-Intestine-Phosphate (CIP) Roche 
Kit Supplier 
Plasmid Plus Midi Kit Roche 
Plasmid Plus Maxi Kit Roche 
RNeasy Kit Roche 
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D.2.5 Standards 
Table D-8: Overview of DNA and RNA standards used 
 
 
 
D.2.6 Computer programs and databases  
Table D-9: Overview of programs and databases used 
 
Gel Extraction Kit Roche 
Quantinova Probe PCR Kit Roche 
Reverse Transcription Kit Roche 
Quick Ligation Kit New England Biolabs 
DIG Northern Starter Kit  Sigma-Aldrich 
Primer Supplier 
100 bp DNA ladder  New England Biolabs 
1 kb DNA ladder New England Biolabs 
Transcript RNA Markers  
0.2-10 kb 
Sigma- Aldrich 
Program/ Database Specification/Supplier 
Kazusa http://www.kazusa.or.jp/codon/  
Codon Usage Exe 
Kindly provided from Benedikt Asbach; customized program 
that calculates CAI according to the formula by Sharp, 1987 
[ref], GC-content and dinucleotide frequencies 
Grapd Pad Prism Used for figures and diagrams  
Chromas Used for sequence analysis 
pDRAW 32 Used for in silico simulation of cloning  
Ape Plasmid Editor Used for sequence analysis and in simulation of cloning in silico 
Step One Software Used for evaluation of RT-qPCR results 
Corel Draw Used for figures 
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 Cell culture techniques 
D.3.1 Cultivation of eukaryotic cells 
All cell culture techniques were performed under sterile conditions in a class II laminar flow hood. 
HEK293T cells were cultivated at 37°C and 5% CO2. Before reaching full confluence, the cells were 
split 1:10. For this, cells were washed with 10 ml PBS and then incubated with 5 ml trypsin/EDTA for 
5 minutes. The reaction was stopped by the addition of DMEM10 Medium and cells were transferred 
into a suitable tube. Cells were then centrifuged at 300g for 5 minutes and the cell pellet was 
resuspended in 10 ml DMEM10. 1 ml of the cell suspension was transferred into a flask with a suitable 
amount of DMEM10. Cell concentrations were determined using trypan blue in a ratio of 1:1 for 
separation between living and dead cells during counting in a hemocytometer. 
Table D-10: Media and reagents for cultivation of eukaryotic cells 
Medium/Reagent Supplier/ Ingredients Additives 
PBS (Phosphate buffered saline) 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 
1.8 mM KH2PO4, adjusted to pH 7.4 with 
HCl 
- 
trypsin/EDTA PAN Biotech - 
DMEM0 (Dulbecco’s Modified 
Eagle Medium) 
Thermo Fisher - 
DMEM10 (Dulbecco’s Modified 
Eagle Medium) 
Thermo Fisher 10% FCS, 1% 
Pen/Strep 
FCS (fetal calf serum) Sigma-Aldrich - 
Pen/Strep 
(Penicillin/Streptomycin) 
PAN Biotech, 10000 U/ml Penicillin, 10 
mg/ml Streptomycin 
- 
Trypan blue  0.4 %(w/v) trypan blue in PBS - 
D.3.2 Transfection of eukaryotic cells  
HEK293T cells were transfected using calcium phosphate precipitation [134]. For this, a defined 
number of cells were seeded one day before transfection in a suitable dish. In general, 2x105 cells 
were seeded in a 3.5 cm dish in a total volume of 3 ml DMEM10 or 1x106 cells were seeded in a 10 cm 
dish in a total volume of 4 ml DMEM10. The desired amount of DNA was diluted in 135 µL H2O. Then 
15 µL 2.5 M CaCl2 were added and the mixture was slowly added to 150 µL 2x HEBS buffer while 
constantly vortexing the solution. After an incubation period of 15 minutes the suspension was added 
to the cells. For transfection of 2x105 cells 2 µg total DNA were used. For transfection of 1x106 cells 
10 µg total DNA were used. 
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Table D-11: Reagents for transfection of eukaryotic cells 
Reagent Supplier/ Ingredients 
Calcium chloride 2.5 M in H2O 
2x HEBS buffer  50 mM HEPES (N-2-hydroxyethylpiperazine-N´-2-ethanesulfonic 
acid), 0.28 M NaCl, 1.5 mM Na2HPO4, pH 7.05 
 Microbiological methods 
D.4.1 Growth and selection of prokaryotic cells 
Bacterial cultures were cultivated overnight in an Erlenmeyer flask with LB medium at 37°C and 
220 rpm. For selection of transformed cells 100 µg/ml of ampicillin was added. 
D.4.2 Transformation of chemically competent cells 
For transformation, 100 µl of competent bacterial cells were thawed on ice and mixed with 1 µg of 
plasmid DNA, followed by an incubation step of 25 minutes on ice. To permeabilize the bacterial cell 
membrane, cells were incubated for 45 seconds at 42°C followed by an incubation step of 2 minutes 
on ice. After that, 500 µl LB medium were added, followed by an additional incubation step of 60 
minutes at 37°C. At the end, the transformed cells were plated on LBamp agar plates. 
Table D-12: Reagents for the transformation of chemically competent cells 
Reagent Supplier/ Ingredients Additives 
LB medium 0,5% (w/v) yeast extract, 1% (w/v) Trypton, 1% (w/v) NaCl, 
pH 7.4 in H2O 
 
LBamp 
medium 
0,5% (w/v) yeast extract, 1% (w/v) Trypton, 1% (w/v) NaCl, 
pH 7.4 in H2O 
100 µg/ml 
ampicillin 
LBamp agar  LBamp medium, 1 % /w/v) agar  
 Molecular biology methods 
D.5.1 Photometric quantification of nucleic acid concentrations 
For photometric determination of nucleic acid concentrations as well as determination of purity, the 
Nanodrop photometer from Peqlab was used. For this, 1.5 µl per sample were loaded onto the 
photometer and measured against a reference sample (e.g. H2O) in a spectral range between 220 
and 300 nm. Using the Beer-Lambert law (E= ε·c·d), the concentration of the sample could be 
calculated from the adsorption at 260 nm, at which an adsorption of 1.0 represents an RNA 
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concentration of 40 ng/ml and a DNA concentration of 50 ng/ml. In the Beer-Lambert Law E is the 
measured absorbance, ε is a wavelength-dependent absorptivity coefficient, d is the path length, and 
d is the concentration of the analyte.  
D.5.2 Isolation of plasmid DNA 
For the isolation of plasmid DNA from bacterial cultures up to 5 ml, the standard method of alkaline 
lysis was performed [135], [136]. For the preparation of higher amounts of plasmid DNA the DNA 
extraction kits (QIAGEN Plasmid Plus Midi/Maxi) from Qiagen were used and isolation was performed 
according to the manufacturer’s protocol. For elution H2O was used.  
D.5.3 Polymerase chain reaction  
The polymerase chain reaction (PCR) [137] was used to amplify  specific DNA fragments. For analytic 
purposes the „GoTaq® Green master mix“ (Promega) was used. To calculate the optimal primer 
annealing temperature, the TM Calculator Software (https://www.neb.com/tools-and-
resources/interactive-tools/tm-calculator) from NEB was used. The reaction protocol is shown in 
table Table D-13: PCR program for reactions with the GoTaq® Green master mix (left) and Phusion 
HF Polymerase (right). For amplification, 100 ng of DNA were used and mixed with water to reach a 
reaction volume of 8 µl which was mixed with 10 µl of the 2x GoTaq® Green master mix as well as 1 
µl of forward and reverse primer. DNA fragments used for cloning were amplified with the Phusion 
High fidelity polymerase (Finnzymes), which has a proofreading function. For those reactions 10 ng 
of DNA were diluted in a volume of 67 µl of H2O and mixed with 20 µl of 5x HF-buffer, 2 µl dNTP-mix 
(10 mM dNTP), 5 µl of forward and reverse primer each as well as 1 µl of Phusion polymerase. The 
reaction protocol is shown in table Table D-13.  
Table D-13: PCR program for reactions with the GoTaq® Green master mix (left) and Phusion HF Polymerase (right) 
TaqPolymerase Temperature Time Cycle Phusion 
Polymerase 
Temperature Time Cycle 
Initial 
Denaturation 
98°C 2 min 1 Initial 
Denaturation 
95°C 2 min 1 
Denaturation 95°C 45 s 
35 
Denaturation 95°C 45 s 
35 Annealing TAN 45 s Annealing TAN 45 s 
Elongation 72°C 1 
min/kb 
Elongation 72°C 30 
sec/kb 
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Final Elongation 72°C 5 min 1 Final 
Elongation 
72°C 5 min 1 
 
Table D-14: Reagents used for polymerase chain reaction  
Reagent Supplier/ Ingredients 
5x HF buffer New England Biolabs  
dNTP-Mix 
New England Biolabs (10 mM ATP, 10 mM CTP, 10 mM GTP, 10 mM 
TTP)   
D.5.4 Fusion PCR 
The fusion PCR was mainly used to generate partially humanized gag-variants. For this, three 
independent Phusion PCR reactions (see D.5.3) with specifically designed primers were performed. 
The first reaction amplified the region of the CMV or LTR promoter, the 5’ UTR up to the desired 
position of the transition between wild-type and humanized gag sequence (PCR1a). An overlapping 
sequence with the second PCR product was added during amplification. In the second reaction, the 
sequence from the desired gag position, the remaining gag ORF and the RRE were amplified (PCR1b), 
together with a complementary sequence to the first PCR product. In the third reaction, both variants 
were fused together (PCR2ab) and subsequently cloned into the pcDNA expression vector. 
 
Figure D-1: Schematic process of a fusion PCR to generate partially humanized gag variants 
Fusion PCR reactions consist of three independent PCR reactions, as described above (here the generation of huAB-wtCDE-
Gag is shown as an example) 
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D.5.5 Standard cloning procedures 
For cloning of genes, standard cloning techniques were used [135]. Vector backbones were digested 
with the desired restriction endonucleases, followed by dephosphorylation with a calf-intestine-
phosphatase (NEB). Purification was performed after agarose gel electrophoresis (see D.5.7) using 
the QIAquick Gel Extraction Kit (Qiagen). Inserts were generated either by direct digestion of plasmids 
with specific endonucleases (NEB) or by PCR amplification followed by enzymatic digestion according 
to the manufacturer’s protocol. Purification was also performed by using the QIAquick Gel Extraction 
Kit after analysis of the DNA by agarose gel electrophoresis. For ligation of inserts and vector 
backbones, the Quick Ligation KitTM (NEB) was used according to the manufacturer’s protocol. The 
complete ligation mix was transformed into chemically competent bacterial cells (see D.4.2) 
D.5.6 Cloning with exocutter BsmBI 
The variants used for the initial localization of the inhibitory motif were generated by the usage of 
BsmBI. For this, synthetically synthesized oligonucleotides representing the different 5’ parts of gag 
were used. The oligonucleotides contained BsmBI cutting sites at their ends, which were used to 
insert the oligonucleotides in an appropriately prepared expression vector. Digestion and ligation 
were performed as described above (D.5.5).  
D.5.7 Agarose gel electrophoresis  
To separate DNA fragments according to their size, agarose gel electrophoresis was performed. For 
this, 1 % (w/v) agarose was heated in TBE buffer and mixed with 50 ng/ml ethidium bromide. PCR 
products amplified with the GoTaq® Green master mix (Promega) were loaded directly onto the gel. 
All other PCR products were mixed with 6x loading dye before loading. For estimation of the size of 
the different products a DNA ladder (1 kb or 100 bp ladder, NEB) was used. The separation of the 
single fragments was performed by running the gel at 80 - 200 V for 30 minutes. The visualization 
was performed by UV-light (302 nm) with the Alpha Imager (HP).  
Table D-15: Reagents for agarose gel electrophoresis 
Reagent Supplier/ Ingredients 
TBE buffer  21.6 g Tris, 11 g boric acid, 8 mL 0.5 M EDTA (pH 8.0) in 1 L H2O 
Ethidium bromide  Roth, 10 mg/ml 
6x loading dye 0.25 % bromophenol blue, 0.25 % xylencyanol, 30 % glycerol 
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D.5.8 Detection of potential cryptic splicing products 
For the detection of potential cryptic splicing products, specific primers were designed that bind 
directly upstream of the major splice donor SD1 and downstream of the splice acceptor SA7. Total 
RNA was isolated and reverse transcribed as described above and subsequently analyzed by agarose 
gel electrophoresis (see D.5.7). Usage of one of the two splice sites would result in the generation of 
a shortened amplification product, which could be detected via agaroses gel electrophoresis.  
Table D-16: Primer for the detection of potential cryptic splicing products 
Primer Sequence 
TS-Splic-Inkl-SD/SA-Fwd GAGGGGCGGCGAC 
TS-Splic-Inkl-SD/SA-Rev CTTCGGGCCTGTCGG 
D.5.9 Generation of completely and partially codon adapted gag-variants 
The completely humanized gag variant was designed by utilization of the KAZUSA codon usage 
database. For this, generally the most abundant codon for human and HIV codon usage was. In the 
case of similar results for human and HIV codon usage (e.g. serine), the procedure was slightly 
changed. For serine, the most abundant codon in human codon usage is AGC, which is also second 
most frequently used in HIV codon usage. Therefore, in this case the second most abundant codon 
in human codon usage was used. Methionine, arginine, and tryptophan were not replaced, since 
there is either only one possible codon, or the order of the codon is usage is identical in both 
organisms. Subsequently the sequence was checked for detrimental sequences like unwanted splice 
sites, inverted repeats or RNA-instability motifs with the GeneOptimizer algorithm [138]. The gag 
sequence then was synthetically produced by Geneart and cloned into a pcDNA3.1 expression vector. 
All partially humanized gag variants were generated either by fusion PCR or BsmBI cloning (D.5.4, 
D.5.6).  
 Working with RNA 
To minimize the risk for contamination with RNases, all working steps regarding RNA were performed 
with filter tips and all working places were decontaminated with RNase AWAY (Thermo Scientific) 
and 1 % SDS (Merck). As far as possible, all solutions and buffers were treated with 1 % DEPC (Sigma 
Aldrich) and autoclaved after 24 hours of incubation.  
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D.6.1 Isolation of total RNA 
For isolation of total RNA, a defined amount of HEK293T cells (normally 1x106 cells) were seeded in 
suitable dishes (e.g. 3.5 cm dish / 6 well plate) and transfected with the desired gag-variants (see 
D.3.2). When cells were confluent, cells were washed with PBS and detached by trypsin/EDTA and 
centrifuged (5 min, 300 g). The cell pellet was resuspended in 1 ml of PBS and transferred into a 
suitable RNase-free 1,5 ml tube. Cells were partially lysed by the addition of 175 µl RLN buffer and 
subsequent incubation on ice for 5 minutes. The cytoplasmic fraction was separated from the nuclear 
fraction by centrifugation (300 g, 2 min, 4°C). Nuclei were then completely lysed by the addition of 
350 µl RLT buffer. From that point, RNA was isolated using the RNeasy Kit (Qiagen) according to the 
manufacturer’s protocol. RNA was solved in RNase-free H2O and stored at -80°C.  
 
Table D-17: Required buffers for the isolation of total RNA  
Buffer  Ingredients/Supllier 
PBS (Phosphate-buffered saline) 137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 1.8 mM KH2PO4, 
adjusted to pH 7.4 with HCl 
RLN buffer  50 mM Tris-HCl pH 8.0, 140 mM NaCl, 1.5 mM MgCl2, 0.5% 
Nonidet P-40, 1000 U/ml Rnase Inhibitor 
RLT buffer  Qiagen (RNeasy Kit), addition of 10 µl β-mercaptoethanol per 1 
ml buffer  
D.6.2 Nuclear Run on assay 
For determination of transcription efficiency, nuclear run on assays were performed. For this, 
HEK293T cells were transfected with the desired variants. After 48 h, cells were harvested and 
washed two times with ice cold PBS. The cell pellet was resuspended in a Nonident P-40 containing 
lysis buffer and incubated on ice for 5 minutes. Nuclei were then harvested by centrifugation (200 g, 
2 min, 4°C) and washed with lysis buffer without NP-40. Nuclei were centrifuged once again (200 g, 
2 min, 4°C), resuspended in 100 µl glycerol buffer and mixed with 200 µl transcription buffer as well 
as 8 µl of biotinylated UTPs (10 mM). After an incubation time of 30 min at 29°C, 6 µl of 250 mM 
CaCl2 and 6 µl of RNase-free DNase I (10 U/μl; Roche) were added to stop the reaction. Total RNA 
was isolated using the RNeasy-Kit (Qiagen) according to the manufacturer’s protocol and RNA was 
eluted in 35µl RNase-free H2O. RNA was mixed with 35 µl M-280 Streptavidinin dynabeads 
(Invitrogen) binding buffer and incubated at 42°C for 20 minutes and 2 hours at room temperature. 
After the incubation, dynabeads were isolated using a magnet and washed two times with 500 μl 
15% Formamid and 2x SSC. After an additional washing step with 1 ml 2x SSC buffer, the dynabeads 
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were diluted in 35 µl of RNase-free H2O.After quantification of the concentration, 200 ng of RNA were 
used for the generation of cDNA (D.6.4) and quantification by real-time qPCR (D.6.5). 
Table D-18: Required reagents and buffers for the execution of nuclear run on assays  
Reagent/Buffer Supplier/ Ingredients 
PBS (Phosphate-buffered saline) 137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 1.8 mM KH2PO4, 
adjusted to pH 7.4 with HCl 
Lysis buffer 10mM Tris/HCl pH 7.4, 3mM MgCl2 , 10mM NaCl, 0.5% NP-40 
Glycerol buffer 50mM Tris/HCl pH 8.3, 5mM MgCl2 , 0.1mM EDTA, 40% glycerol 
Biotin-16-dUTP Roche 
Binding buffer 10mM Tris/HCl pH 7.5, 1mM EDTA, 2M NaCl 
DNase I Sigma Aldrich 
Formamide  Sigma Aldrich  
Rneasy Kit  Qiagen 
D.6.3 Determination of mRNA half-life 
For mRNA half-life determination, 1x106 HEK293T cells were transfected with the desired variants 
(D.3.2) in duplicates and incubated for 48 hours. Half of the cells were harvested using trypsin and 
centrifugation (5 min, 300 g) after 48 hours and cell pellets were stored until RNA isolation. To the 
other half, actinomycin D was added in a final concentration of 2.4µM to block the transcription by 
intercalating in the double strand of the DNA which leads to inhibition of RNA polymerase II. Cells 
were incubated with actinomycin D for 24 hours, then were harvested using trypsin and 
centrifugation (5min, 300g). Thus, for each transfected gag-variant an actinomycin D treated and 
untreated sample could be analyzed. RNA was isolated (D.6.1) and quantification was performed 
after generation of cDNA as described in D.6.4.  Logarithmic plotting of the transcript amounts 
against the time points led to a linear equation of the form  
𝑁(𝑡)
𝑁(𝑂)
= 𝑒−𝑘𝑡 → 𝑙𝑛𝑁(𝑡) = −𝑘𝑡 − 𝑙𝑛𝑁(0), 
with decay constant k representing the slope. Half-life of the mRNA can be calculated by the formula  
t1/2 = -ln2/k. 
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Table D-19: Required reagents and buffers for the determination of mRNA half-life 
Reagent/Buffer Supplier/ Ingredients 
trypsin/EDTA PAN Biotech 
PBS (Phosphate-buffered saline) 
137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 1.8 mM KH2PO4, 
adjusted to pH 7.4 with HCl 
Actinomycin D  Sigma Aldrich 
 D.6.4 Reverse transcription (synthesis of copy DNA)  
Synthesis of copy DNA (cDNA) was performed using the reverse transcription Kit from Qiagen. For 
this, RNA was photometrically quantified (D.5.1). Per reaction, 200 ng of RNA were used while the 
reaction was performed according to the manufacturer’s protocol. The process included also a gDNA 
removal step which has always been performed.  
D.6.5 Quantification of mRNA expression levels by quantitative real-time 
PCR (RT-qPCR) 
For quantification of gag expression on mRNA levels, HEK293T cells were transfected as described 
(D.3.2). After 48 hours, total RNA was isolated using the RNeasy Kit (Qiagen) and cDNA was generated 
using the reverse transcription kit (Qiagen) as described in D.6.1 and D.6.4 which was then diluted by 
the factor of 10. For analysis, 1µl of the diluted cDNA was used and quantification was performed 
using the Bright Green 2x qPCR Mastermix (ABM) or the Quantinova probe Kit (Roche) according to 
the manufacturer’s protocol. For quantification of gag expression, RRE-specific primers were 
designed that bind to the RRE, which was present in all constructs. If the Quantinova probe Kit 
(Roche) was used, an additionally labeled probe was used that lies between the forward and reverse 
primer inside the RRE. Here, the detection principle relies on the 5´–3´ exonuclease activity of Taq 
polymerase. This leads to cleavage of a dual-labeled probe during hybridization to the 
complementary target sequence and fluorophore-based detection. For the Bright Green 2x qPCR 
Mastermix (ABM), only forward and reverse primers were used, since quantification is based on the 
unspecific incorporation of the Bright Green dye in dsDNA molecules. Therefore, a melting point 
analysis was performed, when using the Bright Green 2x qPCR Mastermix (ABM). For all analyses, the 
StepOnePlus real-time PCR system (Applied Biosystems) was used. Besides Quantification of gag 
expression, Neomycin expression was analyzed for normalization. For this, specific primers were 
designed that bind inside the neomycin resistance gene, which was present on all transfected gag 
plasmids. For quantification, a standard curve was generated. For this, Ct values were determined 
using serial dilutions of a linearized plasmid with calculated total copy numbers (from 1x102 to 1x108). 
PCR efficiencies (E) were determined for each reaction. E can be calculated from the slope of the 
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standard curve: E= 10-1/slope. Primers were designed such that the E was approximately 2. The Ct value 
is defined as the cycle number when fluorescence exceeds the background level for the first time.  
 
  
Table D-20: Required kits and mastermixes for quantification of mRNA expression levels by quantitative real-time PCR 
Kits/Mastermix Supplier 
Bright Green 2x qPCR Mastermix-ROX ABM 
QuantiNova Probe PCR-kit  Qiagen 
 
Table D-21: Primers and probes for quantification of mRNA expression 
Primer Sequence 
qNeo fwd GCTATCAGGACATAGCGTTGG 
qNeo rev GAAGGCGATAGAAGGCGATG 
TS-qPCR-RRE-fwd GTTCCTTGGGTTCTTGGGAG 
TS-qPCR-RRE-rev GCCCTCAGCAAATTGTTCTG 
TS-qPCR-RRE-probe ACGTGCAGCCCATAGTGCTTCCT 
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D.6.5.1 Northern blot analysis 
D.6.5.2 Generation of specific RNA probes for northern blot analysis  
For the detection of potentially generated cryptic splicing sites, northern blot analysis was 
performed. For this, specific antisense RNA probes had to be generated. RNA probes were used 
because of the enhanced stability of RNA-RNA hybrids in comparison to RNA-DNA hybrids and 
therefore higher detection sensitivity. Those RNA probes were generated using the DIG northern 
starter kit from Roche. For this a T7- promoter sequence was introduced via the reverse Primer in a 
PCR reaction, to allow the initiation of the T7 polymerase. During this step, which was performed 
with 200ng of the PCR product, Digoxin-labeled uracil was incorporated into the generated RNA 
probe, allowing the following detection.  The reaction protocol is shown in Table D-22 and can be 
seen I detail in the manufacture’s instruction of the DIG northern starter kit 
Table D-22. Process of generating specific RNA probes for northern blot analysis using the DIG Northern Starter Kit 
 
 
 
 
D.6.5.3 Sample preparation 
For the analysis, 2 µg of all RNA samples in a volume of 5µl were mixed with 2 volumes of RNA sample 
buffer as well as 5 volumes of RNA loading buffer and incubated together with the RNA ladder at 
65°C for 5 min, followed by immediate transfer on ice. 
D.6.5.4 Gel electrophoresis  
RNA was then separated according to its size by agarose gel electrophoresis. For this purpose, all 
materials were cleaned with 1% SDS as well as 3% H2O2. The gel was produced by mixing 22.5 ml 10x 
MOPS buffer with 172.5 ml DEPC treated H2O and 2.25 g agarose and subsequent boiling using a 
microwave. As soon as the solution was cooled to 55°C, 30 ml of formaldehyde (37%) were added. 
As running buffer 1x MOPS buffer was used. The gel run was performed for 2.5 hours at 100V.  
D.6.5.5 Blotting of the RNA samples onto a nylon membrane 
Prior to blotting, the gel was washed in three different conditions with shaking at 40 rpm according 
to Table D-23. 
42°C 1 hour 
4°C Add 2 µl DNase 
37°C 15 minutes 
4°C Add 1 µl RNase inhibitor + 1 µl 500mM EDTA 
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Table D-23: Washing steps as preparation of blotting RNA samples to a nylon membrane 
Washing steps Time 
DEPC - H2O (300 ml) 3 x 20 min 
0.05 M NaOH (250 ml) 20 min 
20x SSC Buffer (250 ml) 45 min 
To transfer the RNA samples to a positively charged nylon membrane (Sigma), it was positioned on 
top of the gel. Below the gel, three pieces of Whatman paper were arranged, with the edges of the 
lowest one dipped into 20x SSC blotting buffer. Two pieces of Whatman paper and one layer of 
parafilm were placed on top and on the edge of the membrane. Above, pulp was stacked to a height 
of approximately 15 cm and 2 kg weight was added to ensure overnight blotting (16h) via capillary 
force. 
D.6.5.6 Fixation of RNA 
After blotting, the membrane was washed in 5x SSC buffer for 15 minutes and dried. Fixation of the 
transferred RNA samples was achieved using a UV cross-linking device (Stratalinker 1800) running 
the programme “Auto Cross Link (1200 kJ)”.  
D.6.5.7 Methylene Blue staining 
To control the success of blotting, the membrane was stained with 0.03% methylene blue in 0.3M 
sodium acetate until the ribosomal RNA bands were visible. The membrane was washed in DEPC-
H2O, the rRNA and marker bands highlighted with a pen and a picture was taken with a gel 
documentation device.  
D.6.5.8 Hybridisation 
Each hybridisation solution consisted of 7.4 g DIG Easy Hyb Granules from the Northern Starter Kit 
solubilised in 15 ml DEPC -H2O. The washed membrane was transferred to a hybridization bottle and 
pre-incubated with 10 ml of pre-heated hybridisation solution at 68°C for 30 minutes in an oven. For 
actual hybridisation, the RNA probes were denatured at 99°C for 5 minutes, and 10 µl of the probe 
were added to the remaining 5 ml of hybridisation solution. The solution was added to each 
membrane and incubated at 68°C for 16 hours. 
D.6.5.9 Washing 
Washing of membranes after the hybridisation consisted of two washing steps with pre-heated 
solutions: 
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- non-stringent washing: 2 x 5 minutes at 68°C in 2x SSC Buffer + 0.1% SDS (50 ml each)  
- stringent washing: 4 x 15 minutes at 68°C in 0.2x SSC Buffer + 0.1% SDS (50 ml each). 
D.6.5.10 Detection 
The membranes were washed in maleic acid buffer + 0.3% Tween-20 and blocked with 100 ml 1x 
Blocking Buffer from the Northern Starter Kit for one hour. 5 µl of an anti-DIG antibody with an 
attached alkaline phosphatase from the kit were diluted in 50 ml of the blocking buffer and the 
membranes were incubated for 30 minutes with shaking. After two washing steps with maleic acid 
buffer + Tween-20 for 15 minutes, the membranes were equilibrated in detection buffer for 5 
minutes. The detection was performed as described in the manufacturer’s protocol, using an. The 
visualization was performed on the INTAS device (ChemiLuxPro). 
Table D-24: Buffer and reagents required for northern blot analysis 
Buffer/ Reagent Supplier/ Ingredients Additives 
10x MOPS buffer (pH 7.0) 400 mM MOPS, 60.5 mM C2H3NaO2, 500 mM 
EDTA pH8.0,  
 
20x SSC buffer (pH 7.0) 0.3 M Na3C6H5O7, 3 M NaCl,   
RNA sample buffer 65% CH3NO, 8.5% CH2O, 6.45% 10x MOPS 
buffer, 6.45% DEPC-H2O 
 
5x RNA loading buffer 
20% glycerol (87%), 8mM EDTA (500mM, pH 
8.0), 0.4% bromophenol blue, 30.8% CH3NO, 
2.7% CH2O (37%), 40% 10x MOPS buffer, 1% 
DEPC-H2O 
 
Maleic acid buffer 0.1 M maleic acid, 0.15 M NaCl  
Washing buffer Maleic acid buffer 0.3% Tween 20 
 Detection buffer 0.1 M Tris/HCl, 0.1 M NaCl  
Hydrogen peroxide (H2O2) Sigma Aldrich  
Methylene blue  Sigma Aldrich  
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Table D-25: Primers required for generation of a complementary RRE probe 
Primer Sequence 
TS-RRE-Sonde-NB fwd GATCTTCAGACCTGGAGGAG 
TS-RRE-Sonde mit T7-NB 
rev 
TAATACGACTCACTATAGGGCTCAGCAAATTGTTCTGCTGC 
 
 Protein biochemistry techniques 
D.7.1 Lysis of HEK293T cells 
For analysis of intracellular Gag expression, cells were lysed after transfection. For this, cell pellets 
were washed with Phosphate Buffered Saline (PBS), centrifuged again, resuspended in 150 μl pre-
cooled TDLB (RIPA) Buffer and incubated on ice for 20 minutes. Samples were then sonified for 5 
minutes using a Bioruptor device (Diagenode) at energy level H. Cellular debris was removed by 
centrifugation at 20,000g and 4°C for 5 minutes. All cleared lysates were transferred into a fresh 
Eppendorf tube and total protein amount was quantified by Bradford analysis (D.7.2) 
  
Table D-26: Buffers required for lysis of HEK293T cells  
Buffer/Reagent Supplier/Ingredients 
PBS (Phosphate buffered saline) 137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 1.8 mM 
KH2PO4, adjusted to pH 7.4 with HCl 
TDLB (RIPA) buffer Tris 50 mM, NaCl 150 mM, SDS 0.1 %, Na-desoxycholate 
0.5 %, TritonX-100 1 %, pH 8.0 
 
 
D.7.2  Quantification of total protein amount by Bradford analysis 
For quantification of total protein amounts in cellular lysates, a Bradford assay was performed. 2 μl 
of 1:4 diluted sample lysates were added to 158 μl PBS in triplicates on a 96-well plate (Sarstedt). For 
generation of a standard curve, defined amounts of bovine serum albumin (BSA) from 0 to 5 μg were 
used. 40 μl of the Bradford reagent were then added to each well and it was thoroughly mixed. 
Absorbance at 595nm was detected with an MP Reader 680 photometer (BioRad) and the amount 
of total protein in each sample was calculated based on the standard curve. 
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Table D-27:Buffer and reagents required for quantification of total protein amount by Bradford analysis 
Buffer/Reagent Supplier/Ingredients 
PBS (Phosphate-buffered saline) 137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 1.8 mM 
KH2PO4, adjusted to pH 7.4 with HCl 
Bradford Reagent  BioRad 
Bovine serum albumin Sigma Aldrich 
 
D.7.3 Quantification of Gag expression by p24-Enzyme-linked 
Immunosorbent Assay (ELISA) 
As a measure of Gag expression, the capsid protein (p24) was quantified by an Enzyme-linked 
Immunosorbent Assay (ELISA). For this, HEK293T cells were transfected and harvested as described 
(D.3.2). After incubation of 48 hours either 2 µg of total protein from cell lysates or direct supernatant 
samples were analyzed as follows:  
- Dilutions for supernatants: 1 - 1:10 - 1:100 – 1:1000 in DMEM10 
- Dilutions for lysates: 1 - 1:10 - 1:100 (2 μg total protein in undiluted sample) in DMEM10 
For this, a Nunc Maxisorp 96-well plate (Thermo Scientific) was coated with 0.25 µg of primary anti-
p-24 antibody (M-01, Polymun) per well in 100 µl of coating buffer the day before analysis and 
incubated overnight at 4°C. All washing steps have been performed with the tecan hydroflex ELISA 
washer. Before loading of the dilutions on the coated plate, wells were washed with the tecan 
hydroflex program p24_3x_A, followed by an incubation time of 1 hour at 37°C. After that, wells 
were washed with the tecan hydroflex program p24_6x_A and the biotinylated secondary anti-
p24-antibody (37G12, Polymun) was added in a concentration of 1:10000 in blocking buffer and 
incubated for 1 hour at room temperature. Next, wells were washed with tecan hydroflex 
program p24_10x_A and streptavidin-HRP-conjugate (Roche) was added in a concentration of 
1:10000 in blocking buffer, followed by an additional incubation of 30 minutes at room 
temperature. The streptavidin-HRP-conjugate was washed away by an additional washing step 
(with tecan hydroflex program p24_10x_A). For detection, a TMB substrate was used. 100 μl of 
a 20:1 mix (TMB A: TMB B) were added per well and incubated for 5 minutes. The reaction was 
stopped with 50 μl of 1M H2SO4 per well, and the absorbance was measured with a MP Reader 
680 photometer (BioRad) at 450 nm in triplicates. Gag amounts in each sample were calculated 
based on the p24 standard curve. For creation of a standard curve, recombinant p24 was used. 
Concentration of the standard started at 2.5 ng/ml and was diluted 5 times by the factor of two, 
to reach a minimal concentration of 0,078 ng/ml.   
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Table D-28: Buffer, reagents and antibodies required for quantification of Gag expression by p24 ELISA 
Buffer/ Reagent/Antibody Supplier/ Ingredients 
M01-antibody (anti-p24) Polymun  (AB006) 
37G12- antibody (anti-p24), 
biotinylated  
Polymun (AB005) 
Streptavidin-HRP conjugate  
(500 U/ml) 
Roche  
Coating buffer  100 mM sodium carbonate, pH 9.5 
Blocking buffer  PBS mit 5 % (w/v) BSA 
PBS-T 137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 1.8 mM KH2PO4, adjusted 
to pH 7.4 with HCl, Tween  
TMB-A 30 mM potassium citrate, pH 4.2 
TMB-B 10 mM TMB, 10 % (v/v) Aceton, 90 % (v/v) Ethanol, 80 mM H
2
O
2
 
 
 Analysis of GFP expression by flow cytometry  
For analysis of EGFP expression, HEK293T cells were transfected as described (D.3.2). After 48 hours 
of incubation, medium of cells was removed and cells were washed with 1ml of PBS and harvested 
using trypsin-EDTA. Cells were pelleted by centrifugation (500g, 3min) and washed again with 1 ml 
of PBS. Then, cells were centrifuged again (500g, 5min) and the pellet was resuspended in 1 ml of 
FACS buffer. Analysis of GFP expression was then performed on the FACS Canto II device (BD 
Biosciences) using a blue laser for excitation of GFP at 488 nm and the emission of EGFP by the FITC 
filter (fluorescein isothiocyanate-filter, 530/30). For all analyses, 30000 events were recorded.  
Table D-29: Buffers and reagents required for analysis of GFP expression by flow cytometry 
Buffer/Reagent Supplier/Ingredients 
PBS (Phosphate-buffered saline) 137 mM NaCl, 2.7 mM KCl, 10 mM Na2PO4, 1.8 mM 
KH2PO4, adjusted to pH 7.4 with HCl 
Trypsin/EDTA PAN Biotech 
FACS buffer 1% FCS in PBS  
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 DNA Sequencing 
All sequence analyses were performed either by Seqlab or by GATC. For this, the desired amount of 
DNA was mixed with the specific sequencing primer in H2O according to the instructions of the 
respective company. Results were evaluated with the programs Chromas and Ape.  
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E Results 
 Generation of partially humanized gag variants 
Several studies already analyzed the influence of codon adaptation on viral gene expression and 
consequently viral replication [109]–[111], [128]. All of them underlined the importance of codon 
usage and demonstrated the complex interplay between different biological sequence features and 
processes. In general, viral replication has been used in those studies as a measure of the impact of 
codon adaptation. In this thesis, a systematical approach was chosen to analyze the importance of 
codon usage directly on gene expression. Other biological processes that are involved in viral 
replication, like viral entry, reverse transcription, budding or release of new virions should be 
excluded by using subgenomic reporter constructs (see C.1.7). The Gag protein from HIV-1 was 
chosen as viral model protein for these analyses because of its importance and the availability of data 
from different preliminary studies [59], [112], [114], [139]. It was already shown that the 
humanization of gag leads to an enhanced and Rev-independent protein production. In order to find 
out whether there are positional or additive effects of codon adaptation, the gag-gene was divided 
into five parts, which were gradually adapted to human codon usage, a process here referred to as 
"humanization". The borders of the five parts, named with the letters A-E, were chosen because of 
 
Figure E-1: Schematic illustration of a gag subgenomic construct in general (A) and partially humanized variants (B) 
Gag reporter constructs were expressed under control of the heterologous CMV promoter and contained the 5’UTR, the 
RRE and a polyadenylation site. Based on the wild-type (wt) and fully humanized (hu) gag variant, partially humanized 
variants were generated that can be divided into a 5’-3’ as well as 3’-5’ subset. 
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biological motifs. The boundary between A and B was defined by the second ATG codon within the 
gag sequence, which is might be used for translation inititation in some cases [140]. The C part was 
confined by two restriction sites, SpeI and ApaI, which were used in previous studies of our group. 
The end of part D is determined by the slippery site [27], whereas E ends with the stop codon of gag. 
As a starting point for the partially adapted variants, the wild-type gag sequence from the HIV B-
clade isolate NL4-3 was used, just as the fully humanized version of this gag (hu-Gag or huABCDE). 
Using these two sequences as templates, the partially humanized variants were generated (see 
Figure E-1) by fusion PCR (D.5.4), all containing the desired gag variants under control of a CMV 
promoter (as shown above), together with the HIV-1 NL4-3 5’UTR, the rev-responsive-element (RRE) 
and a BGH-polyadenylation site. Initially, eight partially humanized variants were generated which 
can be divided into a 5’-3’ as well as a 3’-5’ set. For the 5’-3’set, humanization starts at the 5’ part of 
gag (part A) and is enlarged stepwise in 3’ direction (to part E). For the 3’-5’ set humanization starts 
at part E and is enlarged into 5’ direction towards part A. All variants were cloned into a pcDNA3.1 
expression vector. 
 Sequence properties of partially humanized gag variants 
Since codon adaptation necessarily leads to changes of the sequence, variations of specific sequence 
properties occur at the same time, which are known to impact gene expression, like the codon-
Figure E-2: Sequence properties of partially humanized gag variants regarding CAI, TpG / CpG frequency and GC-content 
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adaptation-index (CAI), dinucleotide frequency (e.g. CpG and TpA) or GC-content [141]–[143]. To 
analyze whether possible changes in protein production might possibly be a consequence of 
deviations in those parameters, these properties were evaluated for all partially humanized variants 
by bioinformatic analyses to quantify the differences of these parameters for the variants. As shown 
in Figure E-2, stepwise increase or decrease of humanization by gradual adaptation of gag to human 
codon usage leads to a progressive increase or decrease regarding the analyzed parameters. 
Accordingly, GC content rises from 54% for huA_wtBCDE to a maximum of 60.4% for the fully 
humanized gag variant (huABCDE) and decreases again to a value of 45.5% for wtABCD_huE. The 
wild-type gag possesses a GC-content of 44.0%. An equivalent course can be seen for the codon 
adaptation index and the frequency of dinucleotide CpG. According to the A-rich genome of HIV-1, 
the analysis of the amount of the dinucleotide TpA reaches its maximum for the wild-type gag 
(6.27%) and is minimal for the completely humanized huABCDE variant. Additionally, the five 
different gag parts A-E were also individually analyzed in order to examine how the single parts differ 
between each other, since positional effects of humanization should be analyzed as well. Here it was 
seen that humanized and wild-type variants of the single gag parts differ strongly from each other, 
but there was no significant discrepancy between the single humanized or wild-type parts among 
themselves. The GC- content for example, varies for the humanized sequences between 60.3% (A 
part) and 61.4% (part E) whereas for the wild-type sequence values lie between 41.4% (part C) and 
51.2% (part E). Comparable differences regarding the other analyzed sequence parameters were 
observed. The wild-type fragment D showed the smallest discrepancy in comparison to its humanized 
Figure E-3: Sequence properties of single gag parts (A-E) regarding CAI, TpG / CpG frequency and GC-content: 
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version which might be because of the small size of the fragment. Further, the wild-type parts D and 
E showed decreased TpA levels compared to the wild-type fragments A, B or C.  
 Influence of humanization on gag protein expression of 5‘-3’ adapted 
variants 
Bioinformatic analysis of the 5’- 3’-adapted gag-variants showed a systematic increase or decrease 
in the frequency of the analyzed sequence features (Figure E-2). Of course, it was of interest whether 
increasing humanization also led to a systematic change in protein production. To analyze this, 
HEK293T cells were transfected with the 5’-3’-adapted gag variants. Gag protein production was 
quantified in the supernatants of transfected cells after 48 hours by p24-ELISA. Transfection was 
performed in the presence as well as in the absence of Rev. 
 
Figure E-4: Quantification of Gag expression of the 5’-3’-adapted variants on protein level measured by p24 ELISA 
A) Schematic overview of the 5’-3’ adapted variants and the localization of humanized and wild-type nucleotides. B) 
Relative p24 expression of 5’-3’ adapted gag-variants in the absence of Rev of transfected HEK293T cells. C) Relative p24 
expression of 5’-3’ adapted gag-variants in the presence of Rev of transfected HEK293T cells. D) Influence of Rev on p24 
expression determined by calculating the ratio between expression in the presence and absence of Rev. All experiments 
were performed in biological triplicates.  
To allow for a better comparison of all independently performed experiments, where absolute p24 
amounts vary due to factors such as transfection efficiency, the expression of wild-type gag in the 
presence of Rev was set to 100%. As shown in Figure E-4A, all 5’-3’ adapted variants were expressed 
even in the absence of Rev. Furthermore, it became apparent that the numbers of humanized codons 
directly affected gag expression for the 5’-3’ subset on protein level. Increasing numbers of adapted 
codons accordingly led to an increase in protein production. According to that, for the variant 
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huA_wtBCDE the weakest Gag expression was measured with a relative p24 value of 41%. Further 
humanization of an additional part of gag (part B) led to an enhanced p24 expression of 209%. This 
trend was also true for the rest of the 5’- 3’ adapted variants with p24 levels of ≈636%, 664% and 
760% for the variants huABC_wtDE, huABCD_wtE and huABCDE (huGag). Since the accessory protein 
Rev is needed for wildtype Gag expression (nearly no expression of wild-type Gag in the absence of 
Rev), it was of interest to which extent partially humanized variants benefit from the presence of 
Rev. It turned out that variants with less adapted codons profit to a larger extent from the presence 
of Rev than stronger humanized variants. Correspondingly, the p24 expression of the subgenomic 
variants huA_wtBCDE and huAB_wtCDE rise by the factors of 3.3 (huA_wtBCDE) and 1.9 
(huAB_wtCDE) to relative p24 levels of 134% and 389%, respectively. Those variants that show 
already strongly enhanced p24 levels in the absence of Rev (huABC_wtDE, huABCD_wtE and 
huABCDE), did not benefit by the addition of Rev. As shown in Figure E-4C, the addition of Rev rather 
led to a slight decrease in p24 expression. Calculating the ratios of the expression in presence and 
absence of Rev, led to values of 0.8 (huABC_wtDE), 0.9 (huABCD_wtE), and 0.8 (huABCDE) which 
might be because of the negative effect of transfection of an additional transgene. However, the 
analysis of gag expression of the partially humanized 5’- 3’-adapted variants clearly showed the 
beneficial effect of humanization since it enabled the enhanced expression of all partially humanized 
variants even in the absence of Rev.  
 Effect of Rev inhibition by addition of Leptomycin B on the gag 
expression of the 5’- 3’ adapted gag-variants  
To confirm the Rev-independent expression of humanized variants and an enhanced beneficial Rev-
effect for variants with fewer humanized nucleotides, the expression analysis was performed again 
for the 5’-3’ set in the presence of Rev and Leptomycin B (LMB). LMB is an unsaturated, branched-
chain fatty acid, which inhibits the export of proteins containing a nuclear export signal. The 
mechanism of inhibition is mediated by  the direct binding of leptomycin B to CRM1, which blocks 
the binding of CRM1 to proteins containing the nuclear export signal [144], here especially the Rev 
protein. According to the data presented in E.3, LMB should have a stronger effect on the expression 
of gag-variants with a smaller amount of humanized nucleotides, since those variants rely stronger 
on the Rev-mediated expression. To test this, HEK293T cells were transfected as described and LMB 
was added to the cells in a concentration of 2.5nm immediately after transfection. Since CRM1, which 
is inhibited by LMB exports not only the Gag protein but mediates the export of several cellular 
molecules, the optimal concentration of LMB was determined in several toxicity tests to block the 
export of gag mRNA as good as possible without killing of transfected cells (data not shown). 
Nevertheless, a residual toxicity of LMB could not be prevented. After 48 hours, p24 expression was 
measured in the supernatants of transfected cells by p24 ELISA (Figure E-5). In general, the expression 
levels of the different variants correlated with the number of humanized nucleotides. The weakest 
p24 expression of the partially humanized variants was detected for the huA_wtBCDE (30%) 
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construct, which is the least humanized one. In contrast, the completely humanized variant huABCDE 
showed the highest p24 expression with a relative p24 amount of 329%. The remaining variants lie 
in between with relative p24 levels of 118% (huAB_wtCDE), 224% (huABC_wtDE) and 295% 
(huABCD_wtE). So, as expected, the addition of LMB lead to general impaired expression levels 
because of its toxicity. To point out that the addition of LMB did not affect all 5’-3’-adapted variants 
to the same extent, the impact of LMB treatment was calculated by dividing the relative expression 
levels in the absence of LMB by the expression levels in the presence of LMB (Figure E-5C). Here it 
became apparent that the effect of LMB is higher for those variants with smaller numbers of 
humanized codons, similar to the effect of Rev, shown in Figure E-4D. The LMB ratio of the 
huA_wtBCDE variant was the highest with 4.6, followed by 3.3 for huAB_wtCDE. The residual variants 
huABC_wtDE, huABCD_wtE and huABCDE all showed ratios around the factor of 2 (2.3, 2.0 and 1.9) 
At first glance this might be unexpected, since those variants did not benefit from the addition of Rev 
as shown in Figure E-4D, hence LMB should also not affect the protein levels of those variants. 
However, because of the general impaired protein production in the presence of LMB due to toxicity, 
the reduced p24 level that were used for calculation of the LMB effect lead to values that were higher 
than those calculated for the Rev effect. Anyway, the lower effect of LMB on expression of the 
variants huABC_wtDE, huABCD_wtE and huABCDE compared to the variants huA_wtBCDE and 
huAB_wtCDE indicates the lower beneficial effect of Rev on these variants. 
 
Figure E-5: Quantification of Gag expression of the 5’- 3’-adapted variants on protein level measured by p24 ELISA in 
the presence of Rev and Leptomycin B (LMB). For a detailed description of the analyzed variants see Figure E-4 
A) Relative p24 expression of 5’-3’ adapted gag-variants in the presence of Rev and LMB of transfected HEK293T cells. 
B) Influence of LMB on p24 expression determined by calculating the ratio between expression in the absence of LMB 
(see Fig. E-5C) and the expression in the presence of LMB. All experiments were performed in biological triplicates.  
Therefore, the thesis of a reduced impact of Rev on variants with higher degrees of humanization 
could be confirmed as well as the cumulative effect of humanization, with higher expression levels 
for variants with higher numbers of humanized nucleotides.  
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 Influence of humanization on Gag protein expression of 3‘-5’ 
adapted variants 
To investigate whether besides the cumulative effect of humanization also the position of codon 
adaptation is important for enhanced and Rev-independent gag expression, partially humanized gag 
variants were generated, where humanization was enlarged diametrically opposed to the initial set 
from 3’ to 5’ direction (3’-5’ set). Expression of these variants (wtABCD_huE, wtABC_huDE, 
wtAB_huCDE and wtA_huBCDE) was also analyzed in the absence and presence of Rev on protein 
level. For this, HEK293T cells were transfected with the 3’-5’-adapted gag variants. Gag protein 
production was quantified in the supernatants of transfected cells after 48 hours by p24-ELISA.  
 
Figure E-6: Quantification of Gag expression of the 3’-5’-adapted variants on protein level measured by p24 ELISA 
A) Schematic overview of the 3’-5’-adapted variants and the localization of humanized and wild-type nucleotides. B) 
Relative p24 expression of 3’-5’-adapted gag-variants in the absence of Rev of transfected HEK293T cells. C) Relative p24 
expression of 3’-5’-adapted gag-variants in the presence of Rev of transfected HEK293T cells. All experiments were 
performed in biological triplicates. 
Surprisingly, the expression pattern of 3’-5’-adapted variants differ remarkably from the expression 
pattern of the 5’-3’ set. All 3’-5’ adapted variants showed expression below or just slightly above the 
detection limit. So, in the absence of Rev, stepwise humanization did not lead to stepwise 
enhancement of expression. In contrast to the expression patterns for the 5’-3’ set, no gradual 
increase of gag expression was observed by incremental humanization. Expression of those variants 
could be rescued by the addition of Rev, but only to a level that was comparable to wild-type gag in 
the presence of Rev, which was set to 100% for all experiments. In the presence of Rev, additional 
humanization neither had a beneficial effect on gag expression, since all variants showed comparable 
expression levels. The quantified relative p24 levels lie between a minimum of 100% for the 
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wtABC_huDE variant and a maximum of 129% for the wtABCD_huE. Therefore, analysis of the 3’-5’ 
set underlined the importance of human codon usage at the 5’part of gag for our experiments. The 
direct correlation between Gag protein amount and the number of humanized codons as well as the 
Rev-independent gag expression and enhanced expression levels in general were only observed for 
a humanized 5’part of gag. 
 Characterization of the impact of the 5’ end of the HIV-1 gag on gene 
expression of codon adapted variants 
E.6.1  Analysis of the impact of the first 423 bp at the 5’ end of HIV-1 gag 
The results so far showed that codon adaptation influences gene expression in a positional as well as 
cumulative way, but humanization at the 5’ part of gag seemed to be required for enhanced and Rev-
independent expression Variants that lack 5’ end humanization showed no gag expression in the 
absence of Rev, independently of the number of adapted codons in the rest of the sequence. 
Therefore, it appeared possible that either the 5’ part of wild-type gag contains an inhibitory motif 
or the codon choice of the 5' part influences the protein production level and Rev-dependency in 
 
Figure E-7: Quantification of Gag expression of the further subdivided 3’-5’ variants on protein level measured by p24 
ELISA (modified from [145]) 
A) Schematic overview of the further subdivided 3’-5’ variants and the localization of humanized and wild-type 
nucleotides B) Relative p24 expression of further subdivided 3’-5’ gag-variants of transfected HEK293T cells. Rev was 
added as indicated. All experiments were performed in biological triplicates.  
 Results 
- 59 - 
 
general. To answer these questions Maria Deichner subdivided the 423 bp part A of HIV-1 gag into 
five additional variants with stepwise increases in the number of humanized nucleotides (Figure E-7) 
as part of her bachelor-thesis. Starting with the wtA_huBCDE variant which has wt codons from 
nucleotide 1 to nucleotide 423, for each additional variant 81 nucleotides were additionally 
humanized. This started at the border between part A and B and was done towards the 5’ end of gag. 
In that way, the variants wt1-18, wt1-99, wt1-180, wt1-261, wt1-342, were generated.   
Quantification of gag expression of the additionally subdivided 3’-5’ variants emphasized the 
importance of the 5’ end of HIV-1 gag for enhanced and Rev-independent protein production after 
humanization. The completely humanized variant, which has no wild-type codons (wt0=huABCDE) 
expectedly showed the strongly enhanced p24 expression even in the absence of Rev (498%), which 
is in accordance with the previous results so far. A slightly, but not significantly reduced expression 
level was also seen for the wt1-18_hu19-1500 variant with relative p24 expression of 393%. In 
contrast, the variant with additional 81 wild-type nucleotides (wt1-99_hu100-1500) already 
exhibited significantly impaired p24 levels (28%). For the residual variants with additional wild-type 
nucleotides, gag expression was even more impaired with relative p24 levels of 11% for wt1-
180_hu181-1500 and 17% for wt1-261_hu262-1500. For the variants wt1-342_hu343-1500 and wt1-
423_hu424-1500 (=wtA_huBCDE) p24 expression was just slightly above the detection limit. As 
expected, the wild-type gag variant (without humanization) showed no expression in the absence of 
Rev. These results suggest that a potential inhibitory motif might lie within the first 100 nucleotides 
of HIV-1 wild-type gag since all variants with wild-type codon usage in this area showed significantly 
impaired protein production compared to the fully humanized variant. Therefore, codon adaptation 
of the first 100 nt is required to prevent the dramatic collapse in gag expression. Further, just a low 
number of wild-type nucleotides (18 nucleotides) at the 5'-end do not lead to dramatically impaired 
protein production.  
E.6.2 Analysis of the importance of the first 100 base pairs at the 5’ end of 
HIV-1 gag  
The aforementioned expression analysis showed that wild-type codon usage at the 5’ part of HIV-1 
gag seems to mediate a negative effect on protein production. If the nucleotides from 1-99 are not 
humanized, enhanced gag expression in the absence of Rev is prevented. In order to find out whether 
humanization of all of the first 100 nucleotides is required to abolish impaired gag expression, 
variants were generated that further shorten the part at the 5’ end with HIV codon usage. For this, 
variants were generated by fusion PCR that enlarge the number of wild-type nucleotides stepwise by 
the number of 15 nucleotides (i.e. 5 codons). Starting with a fully humanized variant (without any 
wild-type nucleotides), seven additional subgenomic constructs were generated with either 15 (wt1-
15_hu16-1500), 30 (wt1-30_hu31-1500), 45 (wt1-45_hu46-1500), 60 (wt1-60_hu61-1500), 75 (wt1-
75_hu76-1500), 90 (wt1-90_hu91-1500) and 105 (wt1-105_hu1-1500) nucleotides at the 5’ end of 
HIV-1 gag. Expression analysis for these variants after transfection of HEK293T cells in the presence 
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as well as in the absence of Rev was again performed by collecting the supernatants at 48 hours post 
transfection and performing a p24 ELISA (Figure E-8).  
It became apparent that 60 nucleotides with HIV codon usage at the very 5'-end of the gag gene are 
tolerated in the absence of Rev. All variants with 60 wt nucleotides or less at the 5’ part of gag were 
expressed even in the absence of Rev. The four variants with this feature (wt1-15_hu16-1500, wt1-
30_hu31-1500, wt1-45_hu46-1500, wt1-60_hu61-1500) can be divided into two groups, according 
to their expression levels. The wt1-15_hu16-1500 variant showed comparable p24 levels (507 %) to 
the fully humanized variant (535%). The second group, consisting of the three variants wt1-30_hu31-
1500, wt1-45_hu46-1500, and wt1-60_hu61-1500 showed reduced expression levels compared to 
the fully humanized variant, although only wt1-60_hu61-1500 was significantly reduced compared 
to the fully humanized variant (huABCDE) in an unpaired t-test (with p < 0.05 considered significant 
and p < 0.01 considered highly significant). However, these three variants were still expressed better 
in the absence of Rev than the wild-type construct with Rev (≈ factor of 2), which was set to 100%. 
The three remaining variants (wt1-75_hu76-1500, wt1-90_hu91-1500 and wt1-105_hu1-1500 
 
Figure E-8: Quantification of Gag expression of variants further subdivided within the first 100 base pairs  
A) Schematic overview of the further subdivided variants with focus on the first 100 nucleotides of HIV-1 gag and the 
localization of humanized and wild-type nucleotides. B) Relative p24 expression of these gag-variants after transfection 
into HEK293T cells in the absence of Rev, and C) in the presence of Rev. All experiments were performed in biological 
triplicates. 
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showed expression levels in the absence of Rev only slightly above the detection limit and were highly 
significantly reduced compared to the fully humanized variant. Therefore, it was concluded that the 
15 additional wild-type nucleotides of variant wt1-75_hu76-1500 are involved in impairing Gag 
protein production compared to the variant wt1-60_hu61-1500.  
Co-expression of Rev could rescue variants that lacked expression without Rev. However, with a 
maximum relative p24 level of 89 % (wt1-105_hu106-1500), none of these variants exceeded the 
wild-type gag in the presence of Rev, which was set to 100%. The wt1-15_hu16-1500 variant that 
showed a strongly enhanced gag expression even in the absence of Rev, with more than 5-fold 
enhanced expression levels compared to the reference wild-type gag variant, was unaffected by the 
addition of Rev (relative p24 level of 530 %). For the two variants wt1-30_hu31-1500 and wt1-
45_hu46-1500, the addition of Rev led to an enhanced expression by the factor of 1.6 (relative p24 
level of 369 % in the presence vs 230% in the absence of Rev) or 1.4 (relative p24 level of 380 % in 
the presence vs 286 % in the absence of Rev), respectively. The only variant that showed a reduction 
in p24 expression after the addition of Rev, was the variant wt1-60_hu61-1500. The expression 
decreased from 183 % (without Rev) to 97 % (with Rev), which might be a sign for competitive Rev-
dependent and Rev-independent pathways.  
E.6.3 Localization of a potential inhibitory sequence motif at the 5’ end of 
HIV-1 gag 
To investigate whether the loss in expression is induced by the continuous usage of wild-type codons 
from the start ATG over the first 75 nucleotides of gag or whether one or more smaller parts within 
this region is responsible for the effect, further gag variants were generated that were designed as 
follows. All variants were generated with human codons from nucleotide 91 to the end of the gene. 
In the area between nucleotide 1 and nucleotide 90, different parts with varying length of wild-type 
codon usage were inserted at several positions (Figure E-9A). The first five variants all contained only 
15 wild-type nucleotides, while the rest of gag exhibited human codon usage. The position of the 15 
nucleotides was shifted within the first 90 nucleotides of the 5’part of gag (hu1-15_wt16-30_hu31-
1500, hu1-30_wt31-45_hu46-1500, hu1-45_wt46-60_hu61-1500, hu1-60_wt61-75_hu76-1500, and 
hu1-75_wt76-90_hu91-1500). Additionally, five further variants were generated with at least 30 
wild-type nucleotides at different positions within the 5’ part of gag (hu1-15_wt16-90_hu91-1500, 
hu_1-30_wt31-90_hu91-1500, hu1-45_wt46-90_hu91-1500, hu1-60_wt61-90_hu91-1500 and hu1-
30_wt31-75_hu76-1500). Expression analysis for these variants was performed as before in the 
presence as well as in the absence of Rev. 
As shown in Figure E-9, wild-type codon usage within the first 60 nucleotides of HIV-1 gag had no 
influence on protein production when the residual codons are humanized, consistent with the results 
described above. The three variants hu1-15_wt16-30_hu31-1500, hu1-30_wt31-45_hu46-1500 and 
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hu1-45_wt46-60_hu61-1500 exhibited p24 expression levels comparable to the fully humanized 
variant (huABCDE) in the absence of Rev, indicating that this area does not contain the crucial 
sequence which potentially mediates the inhibitory effect. However, shifting of the 15 nucleotides 
into 3’ direction led to an impaired protein production in the absence of Rev that was also statistically 
highly significant (p < 0.01in unpaired t-test). For instance, the variant hu1-60_wt61-75_hu76-1500 
showed p24 levels slightly above the detection limit in the p24 ELISA, despite the marginally changed 
position of the 15 nucleotides with wild-type-codon usage. In addition, all further variants that 
include wild-type codons between the positions 61 and 75 showed weak p24 expression in the 
absence of Rev, and Gag levels were significantly reduced compared to the fully humanized variant 
huABCDE. The addition of Rev led to enhanced p24 levels mainly for variants with very low gag 
expression in the absence of Rev. Especially the variants hu1-60_wt61-75_hu76-1500 and  
 
Figure E-9: Quantification of Gag expression by p24 ELISA of the further subdivided variants for localization of a 
potential inhibitory motif  at the 5’ part of HIV-1 gag 
A) Schematic overview of the further subdivided variants with focus on the first 90 nucleotides of HIV-1 gag and the 
localization of humanized and wild-type nucleotides B) Relative p24 expression of further subdivided gag-variants of 
transfected HEK293T cells in the absence of Rev, and C) in the presence of Rev. All experiments were performed in 
biological triplicates 
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hu1-15_wt16-90_hu91-1500 showed enhanced relative p24 levels by the factor of 5.3 (hu1-60_wt61-
75_hu76-1500) or 4.3 (hu1-15_wt16-90_hu91-1500). All other variants were only marginally affected 
by the addition of Rev with factors between 1.1 (hu1-30_wt31-45_hu46-1500) and 2.0 (hu1-1-
30_wt31-75_hu76-1500). As observed before, addition of Rev can lead to an enhanced gag 
expression, but only to a level which is comparable to wild-type gag expression in the presence of 
Rev. Taken together, expression analysis of the additionally generated variants with only 15 wild-
type nucleotides at different locations within the first 90 nt of the 5’ end of HIV-1 gag, indicated a 
negative effect of wild-type nucleotides between the positions 61 and 75 of HIV-1 gag. Further, the 
surrounding nucleotides also seem to have some impact on this potential inhibitory motif.  
 Confirmation of the position of the inhibitory sequence motif  
To confirm the localization of the inhibitory motif in the 5’ part of gag, variants with inverted codon 
usage were analyzed. Those variants contained humanized codons between nucleotides 61 and 75 
in a wtABCDE or huBCDE gag gene. It was of interest whether conversely changing codons from wild-
type to humanized codon usage in this area can enhance gag expression for variants with otherwise 
weak expression levels in the absence of Rev. The generated variants were named wt1-60_hu61-
75_wt76-1500 and wt1-60_hu61-75_wt76-423_hu424-1500 (Figure E-10). Gag expression was as 
before alongside the control variants huABCDE, wtABCDE, huBCDE and hu1-60_wt61-75_hu76-1500. 
 
Figure E-10: Quantification of Gag expression on protein level measured by p24 ELISA of variants with inverted codon 
usage for confirmation of a potential inhibitory motif  at the 5’ part of HIV-1 gag 
A) Schematic overview of the further subdivided variants of HIV-1 gag and the localization of humanized and wild-type 
nucleotides B) Relative p24 expression of further subdivided gag-variants of transfected HEK293T cells in the absence of Rev, 
and C) in the presence of Rev. All experiments were performed in biological triplicates 
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Expression analysis showed that changing the nucleotide composition between nucleotides 61 and 
75 from wild-type to human codon usage, indeed led to a significant improvement in gag expression 
for the huBCDE variant. As expected, this variant showed nearly no expression in the absence of Rev 
(relative p24 level of 2.3 %), whereas the same variant with human codon usage only in the short 
stretch between nucleotides 61 and 75 (wt1-60_hu61-75_wt76-423_hu424-1500) showed 
expression levels comparable to the reference variant wtABCDE in the presence of Rev with a relative 
p24 expression of 105 %. In contrast, the variant wt1-60_hu61-75_wt76-1500, which represents a 
wtABCDE with human codon usage between nucleotides 61 and 75 did not benefit from the 15 
humanized nucleotides, with a relative p24 level of 6.8 % in the absence of Rev. As observed in the 
previous experiments, the addition of Rev rescued the variants with initially very low p24 levels (wt1-
60_hu61-75_wt76-1500, wtABCDE, huBCDE and hu1-60_wt61-75_hu76-1500) to levels comparable 
to the reference variant (wtABCDE in the presence of Rev). Therefore, it can be concluded that 
removing the inhibitory motif between nucleotides 61-75 of gag by the changing of codons is 
necessary but not enough for enhanced and Rev-independent protein production. With the 
inhibitory motif inactivated, further humanization of the rest of the gag gene contributes positively 
to an enhanced protein production. 
 Influence of humanization on mRNA expression levels of 5’-3’- and 
3’-5’-adapted variants 
One crucial question regarding the changes in protein production due to codon adaptation as 
described above, is which biological processes are mainly affected. Until now, all analyses have been 
performed on protein level via a p24-ELISA. Therefore, an important issue was, whether changes on 
protein level can also be seen already on the level of mRNA expression and whether the influence of 
the localized inhibitory motif is also true for mRNA expression. Thus, the 5'-3’ and 3’-5’ sets were 
analyzed regarding their mRNA expression levels. To do this, cells were transfected with the desired 
variants and cultivated for 48 hours. Then cells were harvested and RNA isolation was performed. 
The gag mRNA was quantified and normalized to neomycin mRNA by real-time quantitative PCR 
analysis, since all expression plasmids contained a neomycin resistance gene. 
As illustrated in Figure E-11, the mRNA expression levels in general reflected the protein expression 
patterns. For the 5’-3’-adapted variants an enhanced gag expression was seen already in the absence 
of Rev. All variants with 5’ humanization (huA, huAB, huABC, huABCD, and huABCDE) showed an 
enhanced expression compared to the wild-type variant. Further the beneficial influence of 
humanization rises with the amount of humanized nucleotides, comparable to the protein expression 
data (Figure E-4). So, the variant with 423 humanized nucleotides (huA) showed a relative gag mRNA 
amount of 57 %, and the expression rises to 291 % for the variant huAB (717 codon-adapted 
nucleotides). As seen before, the variants huABC (1224 humanized nucleotides), huABCD (1293 
humanized nucleotides) and huABCDE (1500 humanized nucleotides) showed even higher gag mRNA 
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levels with 710 %, 858 % and 805 %, respectively. The addition of Rev had a beneficial effect for the 
variants with lower numbers of humanized nucleotides (huA and huAB). The relative mRNA levels 
rise to 151 % (huA) and 514 % (huAB) by the addition of Rev. For the variants huABC, huABCD, and 
huABCDE that showed already strongly enhanced gag mRNA expression in the absence of Rev, the 
beneficial effect of co-transfected Rev was negligible. This became even more clear by calculating the 
Rev effect for all 5’-3’-adapted variants (Figure E-11D) as ratio of the gag mRNA expression levels in  
 
Figure E-11: Quantification of Gag expression of the 5’-3-’ and 3’-5’-adapted variants on mRNA level by RT-qPCR  
A) Schematic overview of the 5’-3’- and 3’-5’-adapted variants and localization of humanized and wild-type nucleotides. 
B) Relative gag mRNA expression of 5’-3’ and 3’-5’-adapted gag-variants in the absence of Rev in transfected HEK293T 
cells. C) Relative gag mRNA expression of 5’-3’and 3’-5’-adapted gag-variants in the presence of Rev of transfected 
HEK293T cells. D) Influence of Rev on gag mRNA expression (ratio between expression in the presence and absence of 
Rev) for 5’-3’-adapted variants. All experiments were performed in biological triplicates. E) Correlation of gag mRNA and 
p24 expression in the absence of Rev and F) in the presence of Rev 
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the presence absence of Rev. The variant huA benefited the most from the addition of Rev with a 
calculated ratio of 2.7, followed by the variant huAB with a ratio of 1.7. The Rev effect of the variants 
huABC, huABCD and huABCDE was smaller with values of 1.1 (huABC), 0.9 (huABCD) and 1.3 
(huABCDE). 
So, in general, the overall trend of protein expression pattern was reflected quite well for the 5’- 3’ 
as well as 3’-5’-adapted variants. As already seen for gag protein expression, humanization is also 
required for enhanced and Rev-independent gag mRNA expression on mRNA level. In the absence of 
Rev, none of the 3’-5’-adapted variants were expressed, independently of the number of humanized 
codons. For all analyzed variants, gag mRNA expression lies between 1.0 % for variant huBCDE and 
2.2 % for variant huCDE. As expected, the addition of Rev led to enhanced gag mRNA levels for all 3’-
5’-adapted variants. However, as already seen for gag protein expression, none of those variants 
could significantly exceed the reference variant (wtABCDE) in the presence of Rev. Taken together, 
the importance of the humanization of the 5’ part of Gag also seems to be true for mRNA expression, 
since mRNA data correlated very good with gag protein expression profiles of 5’- 3’ and 3’-5’-adapted 
gag variants in the presence as well as in the absence of Rev (Figure E-11E and Figure E-11F). 
 Analysis of transcription efficiency for selected partially humanized 
variants 
Since p24 and gag mRNA expression levels correlated very strongly, it seems like codon adaptation 
influences expression already on the RNA level. This leads to the assumption that humanization 
directly influences mRNA amounts. The potential mechanisms are manifold and range from altered 
stability or transcription efficiency to splicing effects. To address this question which processes are 
affected by synonymous codon usage, different possible biological processes were analyzed that 
could be responsible for altered expression levels by codon adaptation. First, transcription efficiency 
was addressed by performing nuclear run-on assays in the absence of Rev. For this, HEK293T cells 
were transfected with the desired variants. After an incubation period of 48 hours, nuclei were 
isolated by centrifugation and initiated transcription was resumed by the addition of transcription 
buffer, containing biotinylated UTP and elongation was allowed to proceed for 30 minutes. After 
isolating total RNA, newly synthesized molecules were separated by streptavidin-coupled dynabeads 
(see D.6.2). Lastly, RT-qPCR was performed for quantification of this biotin-labelled mRNA molecules. 
Importantly, this assay allows quantification of the newly synthesized mRNA molecules 
independently of other processes that might influence mRNA amount (e.g. stability) [146], [147]. 
For a general survey of the effect of codon adaptation, transcription rate was investigated for 5’-3’ 
(huA, huAB, huABC, huABCD, huABCDE) as well as 3’-5’ (huE, huDE, huCDE, huBCDE, huABCDE)-
adapted variants (Figure E-12). As already shown in Figure E-11B, total gag mRNA levels increased 
continuously for the 5’-3’ set with the length of the humanized sequence part. Further, the 
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expression of the fully humanized variant huABCDE was about eight-fold higher compared to 
wtABCDE in the presence of Rev. In the following experiment, quantification of mRNA levels was 
performed after the purification of newly synthesized molecules to detect possible differences 
regarding the mRNA expression levels between total mRNA and newly synthesized mRNA molecules. 
Indeed, a highly significant difference between the total mRNA amount of the completely humanized 
gag variant (huABCDE) and the purified, newly synthesized mRNA molecules was detected (relative 
total gag mRNA amount 804 % vs relative newly synthesized gag mRNA amount 206 % [p=0.0003, 
unpaired t-test]). The clear difference between the total mRNA levels and the newly synthesized 
levels in the nuclear run-on assay was also detected for the variants huAB, huABC and huABCD and 
huABCDE with p values of at least 0.012. Only for the variant huA no significant differences were 
observed between both assays, most likely due to the generally reduced expression of this variant 
compared to the other 5’-3’-adapted variants.  
In addition, the level of synthesized huABCDE mRNA was only around two times higher compared to 
wtABCDE. This indicates that enhanced transcription rate seems to influence RNA amounts to some 
degree but is not the only reason for the observed differences in total gag mRNA levels. Accordingly, 
the variants huABC, huABCD and huABCDE all showed enhanced transcriptional-rates with relative 
gag mRNA levels of 180 (huABC), 218 (huABCD), and 205 (huABCDE), respectively. Further, the 
variants huA and huAB exhibited comparable levels to wtABCDE, indicating no enhanced 
transcriptional efficiency for these variants. For 3’-5’-adapted constructs, no variant showed 
enhanced transcriptional transcriptional-rates. With relative newly synthesized mRNA amounts of 
104 (huE), 103 (huDE), 89 (huCDE), and 115 (huBCDE), all 3’-5’-adapted variants showed comparable 
mRNA levels to wtABCDE. 
 
Figure E-12: Analysis of transcription efficiency by nuclear run-on assay for 5’-3’ and 3’-5’-adapted variants 
A) Schematic overview of the 5’ -3’and 3’-5’-adapted variants and localization of humanized and wild-type nucleotides. B) 
Relative nuclear gag mRNA level after purification of newly synthesized transcripts for 5’-3’ (left) and 3’-5’ (right)-adapted 
variants. All experiments were performed in biological triplicates. For detailed description of the analyzed variants see Figure 
E-11 
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In prior experiments, a motif surrounding the nucleotides 61 to 75 at the 5’ end of HIV-1 gag was 
detected that impaired gag protein production (E.6.3) in the absence of Rev. Therefore, it was of 
interest, whether this motif has a direct influence on the transcriptional transcriptional-rate. To 
address this question, nuclear run-on assays for the panel of variants that were already used for 
localization and confirmation of the inhibitory motif (Figure E-9 and Figure E-10) were performed. To 
obtain knowledge about the impact on transcriptional transcriptional-rates, RT-qPCR analysis was 
performed before purification of the new synthesized mRNA as well as after the purification. 
 
Figure E-13: Analysis of transcription efficiency by nuclear run-on assay for selected adapted variants 
A) Schematic overview of the adapted variants and localization of humanized and wild-type nucleotides. B) Relative nuclear 
gag mRNA levels before purification of newly synthesized transcripts and C) after purification of newly synthesized 
transcripts. All experiments were performed in biological triplicates. 
It became apparent that all analyzed variants can be divided into two groups: Those whose relative 
gag mRNA levels were enhanced (hu1-15_wt16-30_hu31-1500, hu1-30_wt31-45_hu46-1500, hu1-
45_wt46-60_hu61-1500 and huABCDE) and those whose relative mRNA levels were comparable to 
wtABCDE (hu1-60_wt61-75_hu76-1500, hu1-75_wt76-90_hu91-1500, hu1-15_wt16-90_hu91-1500, 
hu_1-30_wt31-90_hu91-1500, hu1-45_wt46-90_hu91-1500, hu1-60_wt61-90_hu91-1500 and hu1-
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30_wt31-75_hu76-1500). For total nuclear RNA (before purification) the maximal differences 
between enhanced and unaffected variants was 8.2 with the highest mRNA level of 626% (hu1-
15_wt16-30_hu31-1500) and the lowest level of 77% (hu1-60_wt61-75_hu76-1500). Quantification 
of the isolated newly synthesized mRNA showed that all variants can similarly be divided into two 
groups: Those variants whose transcriptional initiation profits from humanization in the given areas 
and those whose transcriptional-rates remained unaffected. The variants hu1-15_wt16-30_hu31-
1500, hu1-30_wt31-45_hu46-1500 and hu1-45_wt46-60_hu61-1500 all were comparable to 
huABCDE whose relative level of newly synthesized transcripts was at 227 %. In contrast, the variants 
hu1-60_wt61-75_hu76-1500, hu1-75_wt76-90_hu91-1500, hu1-15_wt16-90_hu91-1500, hu_1-
30_wt31-90_hu91-1500, hu1-45_wt46-90_hu91-1500, hu1-60_wt61-90_hu91-1500 and hu1-
30_wt31-75_hu76-1500 showed relative synthesis rate of approximately 100%. Nuclear run-on data 
therefore indicates that the enhanced gag expression is only to some degree due to enhanced 
transcriptional initiation. Furthermore, the localized inhibitory motif in the 5’ part of gag influences 
expression level at least to some extent because of altered transcriptional transcriptional-rates. All 
variants that contain wild-type nucleotides between position 61 and 75 and therefore possess the 
potential inhibitory motif, showed impaired relative gag mRNA levels after the purification of the 
newly synthesized mRNA.  
 Determination of mRNA stability of selected gag variants  
Since the differences in transcription efficiency were not sufficient to explain the differences in total 
mRNA levels between the various constructs, additional biological processes must be involved. A 
possible explanation why transcriptional transcriptional-rates represent the varying Gag mRNA levels 
only to some degree, could be the additional influence of differential gag mRNA stability. This 
hypothesis was addressed by performing an RNA stability assay that uses actinomycin D, an inhibitor 
of RNA Pol II, to prevent synthesis of new mRNAs. After transfection of the gag variants and addition 
of actinomycin D, transcription is blocked and existing transcripts get degraded over time in 
dependency on their stability, which allows mRNA half-life determination. Again, for a broader 
analysis of the impact of mRNA stability, the initially generated 5’-3’ and 3’-5’ humanized variants 
were analyzed first. It was determined that the completely humanized gag (huABCDE) mRNA exhibits 
an mRNA half-life of 6.2 hours. Contrary to that, wild-type Gag (wtABCDE) showed clearly reduced 
mRNA stability with a half-life of about 1.7 hours and the variant huA showed a half-life of 3.0 hours. 
Increasing the length of humanization also contributes positively to mRNA stability, since the half-
lives of further 5’-3’-adapted variants increased with additional adapted nucleotides (huAB, 3.5 h; 
huABC, 5.1 h and huABCD, 5.2 h). For the 3’-5’-adapted constructs, all variants without humanized 
nucleotides in the 5’ part of the gene (huBCDE, huCDE, huDE and huE) showed half-lives between 1.7 
h and 2.2 h, which is comparable to that of wtABCDE (1.7 h). Therefore, it seems like humanization 
in the 5’ part of Gag contributes positively to mRNA stability and is required for the additive beneficial 
effect on gag expression by increasing humanization. 
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Figure E-14: mRNA stability analysis for the 5’-3’ and  3’-5’ sets of partially humanized variants.  
Half-lives of 5’-3’ and 3’-5’ adapted variants. Half-lives of gag variants were determined after transfection of HEK293T cells 
and subsequent treatment of cells with the transcription inhibitor Actinomycin D. gag mRNA levels were quantified by RT-
qPCR analysis and used for half-life calculation. All experiments were performed in biological triplicates. For detailed 
description of the analyzed variants see Figure E-11 
Next, it was investigated whether the inhibitory motif in the 5’ part of gag already influences gag 
mRNA stability on its own. Hence, Actinomycin D experiments were performed also for the subset of 
variants with small parts of wild type codon usage in a surrounding humanized context (Figure E-15). 
The variants again can be separated in two groups according to their expression levels. For the first 
group (hu1-15_wt16-30_hu31-1500, hu1-30_wt31-45_hu46-1500 and hu1-45_wt46-60_hu61-1500) 
wild-type codon usage had no influence on mRNA stability. Half-lives of those variants varied 
between 6.3 hours (hu1-30_wt31-45_hu46-1500) and 6.1 hours (hu1-15_wt16-30_hu31-1500), 
which is approximately the same half-life as for the fully humanized variant huABCDE (6.8 hours) in 
this experiment. The second group showed significantly impaired mRNA half-lives. All variants that 
contain wild-type codons surrounding position 75 of Gag (hu1-60_wt61-75_hu76-1500, hu1-
75_wt76-90_hu91-1500, hu1-15_wt16-90_hu91-1500, hu_1-30_wt31-90_hu91-1500, hu1-
45_wt46-90_hu91-1500, hu1-60_wt61-90_hu91-1500, hu1-30_wt31-75_hu76-1500 and wtABCDE) 
belong to this group, indicating a clear negative influence of wild-type sequence at this position on 
mRNA stability. The variant of this group with the longest half-life was the wt46-90 variant with a 
half-life of 2.7 hours. The variantwt1-60_hu61-75_wt76-1500 showed a half-life comparable to the 
wild-type variant with 2.2 h. Interestingly. The variant wt1-60_hu61-75_wt76-423_hu424-1500 
exhibit an enhanced half-life of 4.4 h.  
 Results 
- 71 - 
 
 
Figure E-15: mRNA stability analysis of selected partially humanized variants.  
A) Schematic overview of the adapted variants and localization of humanized and wild-type nucleotides B) Half-lives of 
selected humanized variants. Half-lives of gag variants were determined after transfection of HEK293T cells and subsequent 
treatment of cells with the transcription inhibitor Actinomycin D. Gag mRNA levels were quantified by RT-qPCR analysis 
before Actinomycin D addition and after x h of treatment and used for half-life calculation. All experiments were performed 
in biological triplicates. 
Taken together, it could be shown that the usage of wild-type codons in a specific region of the 5’ 
part of gag significantly impairs mRNA stability. It became apparent that even a small part of 15 
nucleotides is sufficient to decrease the Gag mRNA half-life from 6.8 hours (for fully humanized gag 
variant) to 2.4 h (hu1-60_wt61-75_hu76-1500) or 2.1 h (hu1-75_wt76-90_hu91-1500). These findings 
and the differences in transcription rate might together explain the more pronounced differences in 
total gag mRNA abundance. 
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 Detection of potentially generated cryptic splicing variants 
Besides altered transcriptional efficiency and mRNA stability, mRNA level and therefore also protein 
production can be influenced by splicing effects. All subgenomic reporter constructs were composed 
of a suitable promoter, followed by the 5’UTR of HIV-1, the gag open reading frame as well as the 
rev-responsive element. That means, all analyzed variants contain HIV-1’s major splice donor (SD1), 
which is important for stabilization of the transcripts and necessary for Rev-dependent export [59], 
[60], [114] as well as the splice acceptor SA7 which is located in the 3'-part of the RRE. Although those 
two splicing elements usually do not interact with each other, i.e. there is no canonical SD1SD7 splice 
isoform known, the altered nucleotide sequence of humanized variants might contain motifs 
enabling such a splicing pattern or might even have generated additional splicing donor or acceptor 
sites. Therefore, the creation of cryptic splicing variants that would affect the amount of RNAs coding 
for full-length Gag had to be excluded. This was done by northern blot analysis as well as PCR analysis 
after reverse transcription of isolated mRNA. For northern blot analysis a probe was designed that 
specifically detects the gag mRNA and all potential splicing variants due to its complementarity to a 
short sequence within the 5’UTR upstream of the splice donor SD1. As an additional validation, PCR 
analysis was performed after RNA isolation and reverse transcription. Primers had been designed in 
a way to make sure that potential shorter splicing forms would dominate in PCR analysis because 
those forms would exhibit higher PCR efficiencies. Therefore, the forward primer was designed to 
bind upstream of the splice donor SD1 and the reverse primer to bind downstream of the splice 
acceptor SA7 (Figure E-16). For these experiments, the two reference variants huABCDE and 
wtABCDE, as well as the huBCDE variant were chosen, the latter as a representative for all variants 
with impaired expression having wild-type nucleotides at the 5’ end of gag. As shown in Figure E-16B, 
northern blot analysis showed that no additional splicing forms were generated. In the cytoplasm as 
well as in the nucleus, only one distinct band was detected for all analyzed variants with a length of 
approximately 2300bp which represents the expected transcript length including the length of the 
poly-A-tail. As anticipated, gag mRNA was detectable in the nucleus independently of Rev for all 
variants. Further, the completely humanized variant huABCDE showed the strongest expression. 
Contrary, the three variants were all detected in the cytoplasm in the presence of Rev, whereas the 
variants huBCDE and wtABCDE showed very weak signals in the cytoplasm in the absence of Rev. 
Since the intensity of the detected transcripts was quite low, PCR analysis after RNA isolation and 
reverse transcription was performed as an additional validation that no cryptic splicing products were 
generated. As illustrated in Figure E-16C, all variants showed a single band of the expected size. As 
assumed, cDNA detection was successful in the nuclear fraction for all variants independent of the 
presence of Rev. In the cytoplasmic fraction, the variants huBCDE and wtABCDE were dominantly 
expressed in the presence of Rev. Taken together, these experiments showed that no cryptic splicing 
variants were generated by the humanization of gag and the impaired expression of the huBCDE is 
not affected by altered splicing. 
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Figure E-16: Analysis of the splicing pattern of the variants huABCDE, wtABCDE and huBCDE  
A) Schematic depiction of the subgenomic reporter variants highlighting the locations of the major splice donor SD1 and 
splice acceptor SA7 from HIV-1 as well as primer binding sites for analysis of splicing isoforms by PCR analysis after reverse 
transcription. B) Northern blot analysis of selected subgenomic variants by a specifically designed RNA probe. Because 
northern blot analysis was performed in different experiments and with different arrangement of the variants, different 
pictures from different blots were put together in order to visualize all relevant results in one picture C) PCR analysis after 
RNA isolation and reverse transcription of the selected subgenomic variants with the primers shown in A). D) control of the 
correct separation of cytoplasmic and nuclear RNA fractions. PCR reactions were performed with special primers that 
amplify only products from cytoplasmic (NADH) or nuclear (snRNA) fraction if separation was performed correctly.  
 Impact of the Splice Donor SD1 on gag expression 
From previous studies it was already known that the presence of the splice donor SD1 can impact 
gag expression. Since all subgenomic variants therefore contained the SD1 as part of the 5'-UTR, it 
should be analyzed how far expression levels are influenced by the presence of the major splice 
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donor. To analyze the impact of SD1, three selected variants with mutated and therefore destroyed 
splicing consensus sequence were generated (Figure E-17B). Since humanization had the strongest 
beneficial effect on protein production on the 5’-3’-adapted variants, the three constructs 
huA_wtBCDE, huABC_wtDE and huABCDE (Figure E-17A) were chosen for this analysis as 
representatives of the 5’-3’ set. For this, HEK293T cells were transfected with the three adapted gag 
variants and the gag protein amount in the supernatants of transfected cells after 48 hours was 
quantified by p24-ELISA. Transfection was performed in the presence as well as in the absence of 
Rev. 
 
Figure E-17: Analysis of the impact of HIV-1’s major splice donor SD1 on protein production 
A) Schematic overview of the adapted variants and localization of humanized and wild-type nucleotides. B) Sequence context 
of the major splice donor SD1 within the 5’UTR as mutated and intact form. Mutation of the SD1 was performed for the 
representative variants huA_wtBCDE, huABC_wtDE, huABCDE and wt. C) Relative p24 expression in the supernatants of 
transfected HEK293T cells, in the absence (left) and presence (right) of Rev. 
As shown in Figure E-17C, the presence or absence of the splice donor SD1 of HIV had a negligible 
influence on gag protein levels for all partially humanized variants of the 5’-3’ set that were analyzed 
here. In the presence and absence of Rev, comparable p24 levels for all analyzed variants 
independently of the presence of an intact or mutated splice donor were seen. For none of the 
variants a significant difference between the SD and ∆SD variant was detectable. Further, as 
expected, the wild-type variant wtABCDE showed measurable p24 expression only in the presence 
of Rev. Surprisingly, the expression levels were enhanced for huABC_wtDE and huABCDE in the 
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absence of Rev compared to the expression levels in the presence of Rev. However, this difference 
was not statistically significant and might be an experimental variation. 
 Analysis of expression of partially humanized gag variants under 
control of the LTR promoter  
All analyses described so far were performed with subgenomic gag reporter variants under the 
control of a heterologous CMV promoter. The CMV promoter used is well-known for its strong 
expression and was used in the experiments because it had been shown to lead to efficient gag 
protein production in previous studies [60], [112]. To analyze whether the observed expression 
patterns were dependent of the promoter choice, gag expression under control of the natural LTR 
promoter was analyzed. For this, the gag open reading frame was set under the control of HIV-1’s 
LTR promoter together with the 5’UTR and the Rev-responsive element. In order to cover partially 
humanized variants representing all phenotypes described above, various open reading frames were 
chosen for the analysis. The six variants huA_wtBCDE, huABC_wtDE, huABCDE, wt1-15_hu16-1500, 
wt1-75_hu76-1500, and wtABCDE were selected because of their different expression levels and 
striking phenotypes. HEK293T cells were transfected with the adapted gag variants under control of 
 
Figure E-18: Comparison of gag expression levels of adapted variants either under control of the CMV or the LTR 
promoter 
A) Schematic overview of the adapted variants and localization of humanized and wild-type nucleotides. B) p24 
expression levels of the selected humanized variants under the control of the LTR promoter. C) p24 expression levels of 
the selected humanized variants under the control of the CMV promoter of HIV-1. Data is collated from Figure E-4 and 
Figure E-8, etc. D) Correlation analysis of data from B) and C).  
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the LTR promoter and gag protein production was quantified as described before. For easier 
comparison, the p24 expression levels of the corresponding variants under control of the CMV 
promoter are also shown in .Figure E-18B. The experiments that had been performed to generate 
these data are described and already shown in Figure E-4 and Figure E-8.  
Expression analysis of the selected variants under control of the LTR promoter of HIV-1 showed very 
similar results compared to the corresponding variants under control of the CMV promoter. The 
huA_wtBCDE variant showed the weakest gag expression with relative p24 levels of 48 % (LTR 
promoter) and 41 % (CMV promoter). The variants huABC_wtDE and huABCDE and wt1-15_hu16-
1500 showed significantly enhanced expression levels with relative p24 amounts of 589 %, 654 % and 
575 % (LTR promoter) or 636 %, 760 % and 507 % (CMV promoter), respectively. The negative impact 
of wild-type codon usage at the 5’ end of gag is also true for variants under control of the LTR 
promoter. The variant wt1-75_hu76-1500 as well as the completely wild-type gag variant showed 
relative p24 levels slightly above the detection limit with values of 11 % and 0.02% (CMV promoter) 
and 14 % and 0.03 % (LTR promoter). The good comparability between the variants under control of 
the two promoters becomes even clearer by calculating the correlation between the expression 
levels. The result is depicted in Figure E-18D. The r2 value of 0.97 shows a strong correlation and 
indicates that expression analysis of subgenomic reporter variants under control of the CMV 
promoter is a suitable model to analyze the impact of codon adaptation on protein production.  
 Analysis of the impact of codon adaptation on a quasi-lentiviral GFP 
reporter 
In the previous experiments a positional as well as additive impact of codon adaptation of the HIV-1 
gag gene on protein production was observed. To find out whether these effects are specific for HIV-
1 gag or whether these findings can also be seen for other genes, a quasi-lentiviral EGFP reporter 
system was used. This system was already established in previous studies of our group for the gfp 
gene [60]. In this work EGFP was used instead of GFP because of the enhanced photo stability and 
fluorescence mediated by the exchange of threonine by serine at amino acid position 65. For analysis 
of the impact of codon choice on egfp expression, the desired egfp variants were cloned into the 
pcDNA3.1 expression vector and were flanked by the very 5'-UTR and RRE to ensure comparability 
between the results for gag and egfp In some cases (see below), a sequence from HIV-1 gag was 
placed in front of the egfp open reading frame. In all those cases, the gag sequence was used as a 5’ 
untranslated region, downstream of HIV-1’s 5’UTR and in front of the start codon of egfp (see Figure 
E-19).  
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Figure E-19: Schematic illustration of the egfp subgenomic reporter construct  
A) All variants were expressed under control of a CMV promoter together with the 5’UTR of HIV-1 and the Rev-responsive 
element. B) Subgenomic egfp variant as in A with a partial gag sequence (red) as an additional 5’UTR. 
To analyze how far the previous results can be transferred to the egfp reporter system, partially 
humanized egfp variants were generated. First, the egfp sequence was adapted either to HIV codon 
usage (hiv_egfp) or to human codon usage (hu_egfp). These two completely adapted variants were 
then used to generate partially adapted variants, analogous to the 5’-3’ and 3’-5’ set of gag. For this, 
the 720 bp long egfp-sequence was divided into five equal parts of 144 bp named A-E (Figure E-20A). 
Those variants were then transfected into HEK293T cells and egfp expression was quantified after 48 
hours by flow cytometry.  
Expression analysis of partially codon-adapted egfp variants showed remarkable differences 
compared to expression patterns of partially humanized gag variants. Although a stepwise increase 
in expression with longer humanized sequence parts was observed for the 5’-3’-adapted variants 
((GFP)_huA_hivCDE, (GFP)_huAB_hivCDE, (GFP)_huABC_hivDE, (GFP)_huABCD_hivE) similar to gag, 
no positional effects were observed for the 3'-5'-set. In contrast to the 3’-5’-adapted gag variants, 
where no expression was observed for variants lacking humanization at the 5’ end in the absence of 
Rev, 3’-5’-adapted egfp variants ((GFP)hivA_huBCDE, (GFP)_ hivAB_huCDE, (GFP)_ hivABC_huDE, 
(GFP)_ hivABCD_huE) were expressed even without the addition of Rev. So, for all variants, the 
number of humanized codons directly influenced the expression level. As expected, the strongest 
signals were detected for the completely humanized egfp variant hu_EGFP/ (GFP)_hu_ABCDE with 
relative MFI values of 1344 (without Rev) and 856 (with Rev). However, the variants 
(GFP)_huABCD_hivE and (GFP)_ hivA_huBCDE which both had 576 nucleotides with human codon 
usage, displayed significant differences between each other in the absence as well as presence of 
Rev, indicating that not the number of codon adapted nucleotides alone defines the level of egfp 
expression. Furthermore, 5’-3’- and 3’-5’-adapted variants benefitted similarly from the addition of 
Rev. Here, the variants with fewer humanized codons and therefore lower expression levels like 
(GFP)_ hivA_huBCDE and (GFP)_ hivABCD_huE showed the highest Rev-effect of partially humanized 
variants. The ratio between egfp expression in the presence and absence of Rev was 8.5 for (GFP)_ 
hivA_huBCDE and 5.5 for (GFP)_ hivABCD_huE. The Rev-effect for the wild-type egfp variant was 7.9.  
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Figure E-20: Analysis of the impact of codon choice on codon-adapted egfp variants in a quasi-lentiviral expression system 
A) Schematic overview of the adapted variants and localization of humanized and HIV-like egfp nucleotides. B) 
Quantification of egfp expression of partially adapted variants in the absence of Rev by flow cytometry. Single cells were 
gated and GFP positive cells were analyzed 48h post transfection C) Quantification of egfp expression of partially adapted 
variants in the presence of Rev by flow cytometry. 
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 Influence of the identified inhibitory HIV-1 gag motif on egfp 
expression 
In the previous experiments, an inhibitory motif within the 5’ part of HIV-1 gag was identified that 
negatively regulated the gag expression in general and prevented expression in the absence of Rev 
(see E.6.3E.6). In the following experiments it was analyzed whether the inhibitory motif might 
function in a heterologous, dominant manner after transfer to the egfp expression system.  
 
Figure E-21: Analysis of the impact of HIV-1 gag sequences as 5’UTR in the egfp expression system 
A) Schematic overview of the adapted variants and localization of humanized and wild-type or HIV-like gag and egfp 
nucleotides. B) Quantification of egfp expression of partially adapted variants in the absence of Rev by flow cytometry. C) 
Quantification of egfp expression of partially adapted variants in the presence of Rev by flow cytometry. 
Therefore, different egfp variants with various sequences from the 5’ part of gag as 5'-UTR were 
generated. First, two variants were made with the complete humanized or wild-type A-part of gag 
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(423 bp) in front of the egfp open reading frame. Additionally, three variants were generated with 
either parts of the inhibitory motif (wild-type gag nucleotides 61-75 and 76-90) or a non-inhibitory 
control sequence (wild-type gag nucleotides 46-61) in the context of the humanized A part of gag. 
Lastly, the wild-type nucleotides 46-60, 61-75 and 76-90 were added on their own. In all cases, the 
HIV-1 gag sequences were added as an additional 5’ untranslated region Figure E-21A. For this, the 
start codon of gag was mutated so that the original EGFP's start constituted the first ATG in the 
sequence. All variants were used for transfection of HEK293T cells and quantification of egfp 
expression was performed after 48 hours by flow cytometry.  
Expression analysis showed that transfer of the function of the inhibitory motif from HIV-1 gag is 
limited. Indeed, hu_egfp's expression was almost completely inhibited when the wild-type part A (all 
423 bp) of HIV-1 gag was placed in front of the open reading frame in comparison to hu_egfp alone, 
but the inhibitory sequences (61-75 and 76-90) within the otherwise humanized gag A fragment 
showed no specific effect. The inhibitory motifs alone (15 nucleotides) neither showed a specific 
effect. Apart from the complete humanized A-part of gag, which did not influence expression, and 
the complete wild-type A-part of gag, which impaired expression, all variants showed unspecific and 
only slightly impaired egfp levels. Taken together, it was possible to transfer the inhibitory effect of 
the 5' part of gag with wild-type codon usage to the egfp system, but only when all 423 bp from wild-
type part A were set in front of the egfp open reading frame. It remains to be seen whether shorter 
sequences would exhibit an inhibitory effect. Some of the lastly described experiments were 
performed by Sebastian Einhauser and can be reviewed in detail in his Bachelor thesis [113].  
To sum it all up, it was observed that codon usage at the 5’ part of gag influences not only general 
protein amounts but affects also the Rev-dependency. More specifically, a short motif was identified 
that mediates an inhibitory influence on gag gene expression by influencing gag mRNA amounts. The 
impaired levels of mRNA could be explained as a negative effect of hiv wild-type sequence in this 
special area on mRNA stability as well as transcriptional-rates. The inhibitory effect of this motif was 
only to some degree present in the additional reporter gene egfp. An impaired gene expression was 
only observed when the motif was embedded within the first 423bp of the hiv wild-type nucleotides 
of gag.  
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F Discussion  
The degeneracy of the genetic code and therefore the possibility to encode a specific amino acid by 
more than one codon plays a central role in biology as well as in biotechnology. Organisms depend 
strongly on the utilization of the correct codons, since suboptimal codon choice can result in 
inefficient gene expression and also in impaired or deregulated replication of organisms [111], [128], 
[148]. On the other hand, this biological mechanism allows the manipulation of codon choice for a 
broad spectrum of biotechnological or medical applications. For instance, during the last years, it was 
shown several times that changing the codon usage can result in attenuated viruses that may 
potentially be used as vaccines. Nogales and colleagues showed in 2014 that Influenza A virus can be 
attenuated by codon deoptimization. They generated different variants containing deoptimized 
synonymous mutations in coding regions comprising the entire nonstructural gene of influenza A 
virus. They observed that the fitness of the variants was reduced, while immunogenicity was retained 
[110]. Additionally, several other studies with virus attenuated by changes in codon usage were 
performed [104], [115], [126], [134], [135]. Besides codon deoptimization in order to achieve 
attenuation, codon optimization is a common way to enhance protein production and might also be 
used in this direction for the generation of potential vaccines or antibodies. To use these techniques 
possibly also for the fight against the human immunodeficiency virus, an exact knowledge about the 
underlying molecular mechanisms of how codon choice influences viral gene expression and viral 
replication are required. Different studies have been performed to address this question. Takata et 
al. performed a global synonymous mutagenesis screen and identified cis-acting RNA elements that 
regulate HIV-1 replication. A key mechanism that affected viral replication in this context were 
changes in splicing events [151]. Since HIV replication is a highly structured process where 
chronologically regulated gene expression is inevitable for proper replication, in the present thesis a 
simplified system was used. By transfecting HEK293T cells with subgenomic gag reporter variants the 
direct influence of codon usage on viral gene expression was analyzed, independently of other viral 
processes like infection, uncoating, reverse transcription or budding. Intervention in the regulated 
protein production of HIV could easily lead to the interruption of the replication cycle, which would 
make it difficult to study the exact effect of codon usage on viral gene expression. Another advantage 
of the simplified model system of this work is the independency of immunological aspects like cell- 
or antibody-mediated immune response, which could interfere with the direct effect of humanization 
on gene expression, although this could become an interesting aspect in further experiments. Takata 
et al. recently showed the important role of immunological effects induced by the usage of 
synonymous codons, since CG dinucleotide suppression enables antiviral defense and therefore 
influences HIV-1 replication. [152]. 
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 Generation of partially humanized variants and analysis of gene 
expression  
F.1.1 Generation and analysis of partially humanized gag variants 
In order to analyze possible positional and additive effects of codon adaptation, partially humanized 
variants were generated that differ systematically in their amount and position of humanized codons. 
Starting from a wild-type gag gene (wtABCDE) and a completely humanized gag gene huABCDE, two 
subsets of partially humanized variants were generated by fusion PCR (Figure E-1). For the 5’-3’-set, 
humanization started at the 5’ end of gag and was enlarged into 3’ direction. For the 3’-5-set, 
humanization was performed in the opposite direction. The utilization of synonymous codons 
necessarily goes along with the alteration in certain sequence features. In the last years, different 
groups showed the importance of specific sequence features like dinucleotide frequency on gene 
expression or viral replication. For instance, it was shown by different research groups that CpG/UpA 
dinucleotide frequencies affect viral replication [111], [141]. Therefore, the effect of humanization 
on dinucleotide frequency, GC-content and the codon adaptation index (CAI) was analyzed for the 
5’-3’- and 3’-5’-adapted variants. As expected, a gradual increase or decrease in these parameters 
for the partially humanized variants was observed, according to the A-rich HIV- and GC-rich human 
codon usage (Figure E-2). GC- content, CpG dinucleotide frequency rose with increasing number of 
humanized nucleotides, whereas TpA dinucleotide frequency decreased with increasing 
humanization. Since the codon adaptation index (CAI) was used as the crucial parameter for the 
optimization process, it logically rose with increasing humanization. Unexpectedly, these 
bioinformatics analyses could only predict expression data for one subset (5’-3’) and did not reflect 
the impaired and Rev-dependent expression of gag for 3’-5’-adapted variants. Further, the 
differences between the single Gag parts (A-E) were too small to explain the observed importance of 
the A-part of Gag (Figure E-3). These findings indicate that sequence features like GC-content, 
dinucleotide frequency and codon adaptation index does not explain the effects on protein 
production alone. Gag expression differed significantly between the two main subsets (5’-3’ and 3’-
5’) of partially humanized variants. For the 5’-3’ part, a continuous positive effect of humanization 
on gag expression (on protein and mRNA level) was observed. Further, every additional part of gag 
that was humanized resulted in a stepwise increased gag expression, until the maximum for the fully 
adapted version was reached, which is in accordance with the bioinformatic analysis. Additionally, all 
5’-3’-adapted variants were already expressed in the absence of Rev (Figure E-4). Further, variants 
with lower numbers of humanized codons and therefore lower expression levels in the absence of 
Rev (huA and huAB) benefitted stronger from the addition of Rev than variants with a higher number 
of humanized codons and consequently higher expression levels. For those less humanized variants, 
the Rev-Crm1-mediated export pathway for gag mRNAs plays a crucial role. However, this export 
pathway seems to be less efficient for stronger adapted variants because addition of Rev had nearly 
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no influence on the expression of those variants. It might be that gag transcripts are exported out of 
the nucleus, maybe because of higher binding efficiency to the additional export factor and therefore 
only a negligible amount of gag mRNA remains for the Rev-Crm1 pathway. Surprisingly, the finding 
of a stepwise increase in expression by expansion of the sequence part with human codon usage was 
only true for the 5’-3’- but not for the 3’-5’-set (Figure E-6). For the variants that lack 5’ humanization, 
nearly no expression was detectable in the absence of Rev. Furthermore, for these variants it was 
irrelevant how many codons were humanized. As long as the A-part of gag was encoded by wt 
codons, expression could not be enhanced by additional humanization, i.e. even the variant huBCDE 
that contains nearly 72% of humanized codons but acts like the wild-type variant. Accordingly, the 
correlation between amounts of humanized codons and gag expression which was observed for the 
5’-3’-set was not true for the 3’-5’-set. These findings support the theory that the A-part of HIV gag 
might contain a potential inhibitory motif, which negatively regulates gag gene expression and does 
not allow gag expression in the absence of Rev. The phenomenon of the function of the inhibitory 
motif seems to be superordinate compared to the other effects of codon adaptation and prevents 
their impact on gene expression. Co-transfection of Rev led to gag expression comparable to wild-
type gag expression, indicating that the export pathway mediated by Rev is not affected by the 
number of humanized codons if humanization is not present at the 5’ part of gag. The particular 
effects of Rev could be reversed by the addition of Leptomycin B (LMB) (Figure E-5). LMB inhibits the 
export of proteins containing a nuclear export signal by by competing for binding to CRM1. Since 
Crm1 also mediates the export of several cellular molecules, a general negative effect of LMB on 
protein production was observed, likely because of an unspecific toxic effect on the transfected cells. 
For example, a reduction of the factor 1.9 was observed for the completely humanized variant 
huABCDE. 
F.1.2 Generation and analysis of partially humanized egfp variants 
It was also of interest whether the findings regarding stepwise codon adaptation were specific for 
the gag reporter gene used or whether the effects are similar for a different reporter gene. 
Therefore, egfp was used in the quasi-lentiviral expression system by altering its codon usage to that 
of HIV genes for further analysis. First, it was tested how stepwise codon adaptation influences gene 
expression for egfp in general. For this, egfp was divided into five parts of the same size and adapted 
stepwise to human or HIV codon usage. It was found that the expression levels for 5’-3’ egfp 
adaptation were comparable to gag expression data for 5’-3’ adaptation. Again, a stepwise increase 
in humanization enhanced protein production systematically. Starting with a Rev-independent but 
relatively weak expression of (GFP)_huA_wtBCDE, the MFI was enhanced with increasing numbers 
of humanized nucleotides. The maximum was reached for the fully humanized egfp variant. Contrary 
to the findings of the necessity of 5’ adaptation of gag to human codon usage, egfp variants with 
HIV-like codon usage at the 5’ part were also expressed in the absence of Rev. In addition, a stepwise 
decrease in expression by reduction of humanization was observed. These findings strongly support 
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the theory of an HIV-gag-specific phenomenon and contradicts the possibility of a general 
importance of humanization at the 5’ end.  
 Localization and examination of the inhibitory motif within the 5’ part 
of HIV-1 gag 
In order to find the precise localization of the potential inhibitory motif, various additional partially 
humanized variants were generated (see E.6). Firstly, the 423 bp of the gag open reading frame (part 
A) of HIV-1 were divided into five additional parts with stepwise increase in the number of humanized 
nucleotides in a 3'-5'-direction. Expression analysis of these constructs showed that the inhibitory 
motif seems to lie within the first 100 nucleotides of gag (Figure E-7). Therefore, further partially 
humanized variants were generated and their expression was analyzed. It turned out that wild-type 
codon usage in the region of nucleotides 61-75 led to a nearly complete loss in gag expression, 
whereas a fully humanized gag variant with wild-type codon usage between nucleotides 46 and 60 
showed no loss in expression. To confirm the findings regarding the position and function of the 
inhibitory motif, also variants with inverted codon usage were generated. For this, for the variant 
huBCDE, which showed no gag expression in the absence of Rev, the nucleotides 61-75 were changed 
from wild-type codons to humanized codons. This resulted in a partially abolition of the inhibitory 
effect by elimination of the potential inhibitory motif (Figure E-10).These findings indicate that a 
small number of changed nucleotides at this certain position within the 5’UTR of gag play a crucial 
role in gene expression and a change of these nucleotides alters protein levels dramatically. It would 
be thinkable that the identified motif might mediate e.g. an interaction between the transcript and 
an RNA binding protein. Dependent of the hypothetical RNA-binding protein this could lead to altered 
RNA stability or export, which would directly influence protein production. Further, the questions 
remain whether the effect of the inhibitory motif is specific for gag and to what extend the sequence 
context influences the observed inhibitory effect of the motif.  
For further characterization of effect of the identified motif, the wild-type nucleotides as well as 
other 15 nucleotide-long wild-type sequences either alone or in context of the A-part of Gag, was 
transplanted as a 5’UTR in front of a humanized egfp open reading frame. Expression analysis of 
those variants showed that the wild-type A-part, but not a humanized A-part, led to impaired 
expression of the humanized egfp, which shows that the negative effect observed for gag expression 
can be dominantly transferred to egfp. However, the additional variants with either the potential 
motif alone, or in the context of a humanized A-part of gag, did not lead to a comparably impaired 
expression as observed for the gag reporter gene. An obvious reason for the unsuccessful transfer of 
the inhibitory effect from gag to egfp is the importance of a broader sequence context. Only if the 
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inhibitory motif is surrounded by further wild-type nucleotides, an impaired gene expression is 
observed. Whether this effect is mediated in this case by the inhibitory motif, or the additional wild-
type nucleotides, is unknown. A molecular explanation of this phenomenon might be differences in 
co-transcriptional mRNA folding of these variants (see F.3.3). 
 Molecular mechanisms that contribute to altered expression of 
partially codon-adapted genes 
Besides characterization and localization of the inhibitory motif, possible molecular mechanisms that 
lead to the observed effects on gag expression should be determined Regarding the effects of 
synonymous codon usage on gene expression and their underlying mechanisms two phenomena 
must be distinguished. The first aspect is a general dependency of the protein production from the 
number of humanized codons. Accordingly, humanization of the egfp open reading frame lead to 
enhanced expression levels. This was true for the 5’-3’ as well as for the 3’-5’-adapted egfp variants. 
The same effect was observed for 5’-3’-adapted HIV gag variants. An exception to this rule was 
detected for gag variants that lack humanization at the 5’-part which seems to represent the second 
aspect, namely the inhibitory impact of a short sequence of HIV wild-type codons on gene expression. 
An aspect that seems to be a special feature of HIV gag. 
F.3.1 Molecular mechanisms that contribute to the general dependency of 
protein production from the amount of humanized codons 
F.3.1.1 Influence of translation on altered gene expression  
Different studies regarding the impact of synonymous codon on gene expression showed a clear 
connection between RNA and protein levels [59], [60], [101], [153] Therefor, RT-qPCR analyses were 
performed to determine the gag mRNA expression for the partially humanized variants. 
Quantification of mRNA expression showed relative levels comparable to p24 amounts for the 5’-3’- 
as well as the 3’-5’-set, indicating a major importance RNA levels in the context of codon adaptation. 
These findings already point to a minor effect of synonymous codon usage on translational effects. 
The influence of codon adaptation on translation has been under debate for years. One common 
theory is that synonymous mutations influence protein abundance by changes in translation 
efficiency [154]–[156], a fact which may hold for many cases in prokaryotes and is often implied as 
affecting heterologous gene expression e. g in. E. coli. However, the influence on translation by itself 
is not enough to account for effects of synonymous codon usage in higher organisms. Chen et al. 
quantified the impact of synonymous codons on mRNA level by analyzing over 3000 GFP variants in 
yeast. They could show a positive correlation between mRNA levels and codon usage bias, which 
points to a direct effect of synonymous mutations on transcript concentration [99]. Further studies 
point into the same direction. Kholiswa et al. showed in 2008 that transfection of Jurkat cells with 
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codon-optimized gag mRNAs only led to small increases in gag production over wildtype mRNAs, 
whereas transfection of optimized DNA resulted in a very large enhancement of expression [100]. 
Furthermore, also our group could show that codon-usage mediated inhibition of HIV-1 gag 
expression in mammalian cells occurs independently of translation [153]. Additionally, in a recent 
thesis of our group the influence of codon adaptation on translation was analyzed in detail. For this 
a Modified Vaccinia Virus Ankara (MVA) T7 based expression system was used. Selected partially 
humanized gag variants with remarkably impaired or enhanced expression levels were cloned into a 
pT7 expression vector, where the gag gene was expressed from a T7 promoter. Since HEK293T cells 
do not have a T7 RNA Polymerase, expression of gag only takes place when a T7 polymerase is added 
to the system. This was done by infection of transfected cells with the MVA-T7. Since poxviral vectors 
replicate exclusively in the cytoplasm, an expression system independent from nuclear processes 
could thus be used, which allowed direct monitoring of the impact of codon adaptation on 
translation. The analysis of the variants hu_ABCDE, wtABCDE, huA_wtBCDE, wtA_huBCDE and 
wtABCD_huE which cover all types of partially humanized variants with remarkable phenotypes 
differed clearly between each other in the subgenomic gag reporter system. Interestingly, in the 
MVA-T7 expression system none of the variants showed significant differences in their expression. In 
the presence, as well as in the absence of Rev, all variants showed comparable expression levels to 
each other [113]. These results confirm the theory that codon adaptation primarily influences gene 
expression on RNA level instead of translation.  
F.3.1.2 Influence of transcriptional efficiency on gene expression  
The process of RNA surveillance itself is a complex topic in which several processes are involved [157], 
[158]. Firstly, the export of mRNAs into the cytoplasm is a crucial point for correct gene expression. 
But, in all analyses, the cytoplasmic RNA levels correlated strongly with the nuclear levels. As shown 
e. g. in the northern blot analysis (Figure G-1), the enhanced gag mRNA expression was observed in 
the nuclear as well as in the cytoplasmic RNA fraction. Therefore, export effects seemed to play a 
minor role for the altered expression level of the partially humanized variants. Two other relevant 
factors, which influence the number of transcripts, are transcriptional activity as well as mRNA 
stability. To measure the transcriptional activity, nuclear run-on assays were performed. For the two 
main sets (5’-3’ and 3’-5’) it was observed that codon usage indeed effects the transcriptional-rate, 
but only when the 5’ part of gag was humanized. The variants huA_wtBCDE and huAB_wtCDE 
showed comparable transcriptional-rates to wtABCDE, indicating that transcriptional efficiency was 
not influenced for these variants. The constructs huABC_wtDE, huABCD_wtE and huABCDE showed 
enhanced transcriptional-rates, which points to a positive effect of codon adaptation on 
transcriptional activity. For the 3’-5’ adapted variants, where the 5’ part of Gag consists of wild-type 
codons, further humanization of the remaining part had no effect on the transcription rate. However, 
the differences between the transcriptional-rate of the adapted variants, especially between 
wtABCDE and huABCDE were clearly lower (factor ≈2) than the differences in overall mRNA 
 Discussion 
- 87 - 
 
expression (factor ≈7), indicating that codon adaptation influences transcriptional activity, but 
further processes must be involved 
F.3.1.3 Influence of mRNA stability on altered gene expression  
Different studies could show a connection between codon optimality and mRNA stability. For 
instance, it was shown in 2015 by Presnyak and colleagues that codon optimality is a major 
determinant of mRNA stability [Ref]. By genome-wide RNA decay analyses, they revealed that stable 
mRNAs are enriched in optimal codons, whereas unstable mRNAs contain predominantly non-
optimal codons. The substitution of optimal codons by suboptimal ones resulted in a clear 
destabilization of mRNA. Contrary, the converse substitution significantly increased stability [159]. 
Moreover, Harigaya et al. examined the association between codon optimality and mRNA stability in 
the fission yeast Schizosaccharomyces pombe. They observed a genome-wide association between 
codon optimality and mRNA stability, pointing to an evolutionary conservation of the phenomenon 
[160]. These findings are in accordance with the result for the constructs analyzed in this thesis 
regarding mRNA stability. To address this issue, Actinomycin D, an inhibitor of the RNA polymerase 
was used for mRNA half-life analysis. For the 5’-3’-adapted variants, it was observed that additionally 
humanized parts of Gag contribute positively to mRNA stability, whereas no effect was observed for 
the 3’-5’-adapted variants. Again, the data suggests a beneficial effect of humanization under the 
precondition of humanization at the 5’-end of gag. A possible explanation for the general 
improvement of mRNA stability by humanization is the rising content of CG base pairs and thereby 
increasing thermodynamic stability. However, since the half lives of all 3’-5’-adapted variants were 
unaffected regardless of the number of humanized codons, the underlying mechanisms seems to be 
more complex. 
F.3.2 Molecular mechanisms that contribute to the function of the inhibitory 
motif on protein production 
In general, the inhibitory effect could be mediated by one of different cellular processes or, more 
likely, by an interplay of several mechanisms. For instance, it would be possible that changes in codon 
usage could affect processes like mRNA export, transcription efficiency, RNA stability or even 
translation. Experimental data from this thesis as well as earlier studies showed a direct connection 
between RNA level and protein production in the context of synonymous codons (see E.8 and [153]). 
Because of that, also the set of variants with a small part of wt codon usage at the 5’ part in a 
humanized gag version were analyzed by nuclear run on assays. It became apparent that the 
identified inhibitory motif negatively influences the transcription rate, since all variants that contain 
wild-type codon usage surrounding the area of 61-75 exhibits transcriptional activity comparable to 
wt_ABCDE (see Figure E-13). A possible explanation could be a changed mRNA secondary structure, 
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which allows better accessibility for proteins involved in transcription elongation. For this, it would 
be of interest to identify possible interaction partners of the gag mRNA in future experiments. 
Besides transcription rate, the stability of mRNAs is a second major aspect that influences RNA and 
therefore also protein levels. So, mRNA stability tests were also perfomed with the variants with 
small parts of wt-codon-usage at different positions in the 5’ part of hugag that were generated for 
localization of the inhibitory motif. Stability analysis of those variants showed that only 15 wt 
nucleotides among an otherwise completely humanized gag gene could antagonize the positive 
effect of humanization of the rest of the gene. It was observed that all variants that in some way 
contain nucleotides from the inhibitory motif showed mRNA stability comparable to wtABCDE, 
regardless of the codon choice of the rest of the gene. A reason for this phenomenon could be a 
change in the mRNA secondary structure, which probably make those transcripts more accessible for 
RNase-dependent degradation. Further, an interaction with a variety of proteins involved in different 
RNA degradation pathways would be possible. Again, an altered secondary structure could influence 
these pathways by making the transcripts more or less accessible for the potential interacting 
proteins.  
F.3.3 Influence of changed mRNA secondary structures on altered gene 
expression  
According to the theory above, folding of mRNAs was predicted with the mfold algorithm, a tool 
which allows the prediction of possible RNA folding forms according to their thermodynamic features 
[161]–[164]. For all analyses, the 5’-UTR and the first 95 nucleotides were analyzed in order to focus 
on that part of gag that was found as decisive for gene expression. The results are shown in Figure 
F-1. As expected, the variant wtABCDE showed the least stable form according to the mfold 
prediction with the highest G-value of the variants assessed. The larger number of A-nucleotides 
results in more open loops which contributes negatively to the thermodynamical structure (see 
Figure F-1B). Conversely, the thermodynamically most stable form is the completely humanized 
variant huABCDE with a free energy value of -65.34 kcal/mol. In line with the enhanced GC content, 
the predicted structure shows only few regions with open loops. Interestingly, the ∆G value is 
remarkably reduced for the variant hu1-60_wt61-75_hu76-1500, since the introduction of 15 wild-
type nucleotides at this position resulted in the generation of an additional open loop structure 
between the nucleotides 150 and 184 in Figure F-1D. The ∆G value was clearly lower compared to 
the completely humanized gag variant (∆G = -54.87 kcal/mol). In contrast, this was not the case for 
the variant hu1-45_wt46-60_hu61-1500. Despite the same number of wild-type codons the open 
loop structure is not present in the predicted secondary structure (Figure F-1C), which led to a similar 
∆G value of -62.87 kcal/mol in comparison to huABCDE. These results are in accordance with the 
expression data on protein as well as RNA level, since a thermodynamically less stable structure could 
result in altered interactions with proteins that might regulate RNA degradation processes.  
 Discussion 
- 89 - 
 
As mentioned above, the RNA surveillance machinery is a complex system encompassing several 
proteins that interact with the RNA molecule like Tap, Adar or Dcp2. To further address and test this  
 
Figure F-1: Prediction of mRNA secondary structures for selected partially humanized variants, based on the mfold 
algorithm.  
The calculated free energy and a schematic illustration of the particular variants are shown. The start codon for each 
variant is marked with a blue arrow. Also, the 5’ and 3’ ends of the sequence are indicated. The relevant generated open 
loops that influence thermodynamical stability are depicted in yellow 
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hypothesis, RNA-protein interaction analyses like an RNA pull-down assay could be performed in 
future experiments.  
Interestingly, mRNA secondary structure predictions of egfp variants along with their 5'-UTRs, 
harboring the gag sequence parts where applicable, showed indeed a crucial difference to those that 
were performed for HIV-1 gag. The negative effect on thermodynamic stability of wild-type 
 
Figure F-2: Prediction of mRNA secondary structures for selected partially humanized egfp variants generated by the 
mfold algorithm.  
The calculated free energy and a schematic illustration of the particular variants are shown. The start codon for each 
variant is marked with a blue arrow. Also the 5’ and 3’ ends of the sequence are indicated 
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nucleotides 61 to 75 of HIV-1 was not true for secondary structure predictions of egfp. As shown 
below, the wild-type A part led to a dramatically impaired stability when it was set in front of the 
egfp open reading frame compared to the humanized A part (∆G = -143.6 kcal/mol vs ∆G = -216.8 
kcal/mol). However, this negative impact on stability was not seen if the humanized A-part contains 
wild-type nucleotides within the positions 61-75 (Gag_huAwt61-75_hu_EGFP). Compared to the G 
value of -216.8 kcal/mol for Gag_huA_hu_EGFP, the gag wild-type nucleotides 61-75 within the A-
part of gag led indeed only to a marginal difference in thermodynamic stability (∆G = -218.4 
kcal/mol). This could be a reason why the negative effect on expression of the inhibitory motif was 
only seen for the gag variants but not for the egfp variants.  
F.3.4 Influence of splicing on altered gene expression  
Besides influencing RNA stability and efficiency, splicing is a key determinant in regulation of 
transcript amounts. So, splicing is a fundamental process in RNA surveillance and also several studies 
on synonymous codon usage showed a connection between splicing effects and protein production. 
Lately, Takata et al. showed that the usage of synonymous codons could lead to perturbed RNA 
splicing, which resulted in defect replication of HIV. In their study, they analyzed sixteen HIV proviral 
mutants with clusters of synonymous codons, resulting partly in replication defect mutants. One 
group of those replication incompetent proviruses showed clearly perturbed RNA splicing [151]. 
Additionally, Mueller et al. showed in 2014 that RNA structure restricts HIV-1 splicing at the major 
splice donor site and that splicing directly influences viral fitness [165]. Although in this present thesis 
no replication competent virus was used, it had to be examined to what extent splicing effects could 
influence the eventual gag production in the experiments, especially because the subgenomic 
reporter constructs contained the major splice donor (SD1) in the 5’-UTR and the weak splice 
acceptor SA7 in the sequence of the RRE (see Figure E-16). To investigate the effect of the major 
splice donor, variants with mutated SD1 consensus sequence were generated to inactivate the splice 
donor. For this, point mutations were introduced into selected variants to destroy the splice donor 
sequence. Expression analysis of these variants showed that the enhanced protein production of the 
5’-3’ partially adapted variants was independent of the presence or absence of the splice donor, since 
the p24 expression data for the analyzed variants with or without the major splice donor correlated 
very strongly. This is in accordance with previous findings of our group that showed that codon-
optimized gag variants showed enhanced expression levels independently of the SD1 [59]. 
A second aspect that had to be excluded is the potential generation of cryptic splicing sites. Since the 
usage of synonymous codons always goes along with an altered nucleotides sequence, there is the 
potential risk of generating additional splice acceptor or splice donor sites that could interact with 
each other or with the present SD1 or SA7 sites. Generation of cryptic splicing products could 
significantly alter protein production and therefore had to be excluded. This was done by two 
different strategies. Firstly, RNA from transfected cells was isolated and reverse transcribed. After 
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that, cDNA was analyzed with primers that would allow the detection of potential additional splicing 
products because of their design to bind upstream of the splice donor SD1 (forward primer) and 
downstream of the splice acceptor SA7. Analysis was performed with the gag variants huABCDE and 
wtABCDE as well as wtA_huBCDE, since the latter variant showed the unexpected loss in gag 
expression. Secondly, the same variants were analyzed by northern blot analysis, which is a suitable 
method to visualize mRNA molecules. For this, an RNA probe was designed that binds upstream of 
the splice donor to make sure that the probe target sequence would not be lost in case of splicing. If 
cryptic splicing variants would be generated by codon adaptation, additional bands would have been 
detected in the northern blot analysis. Since this was not the case, the generation of cryptic splicing 
effects that influence protein production could be largely excluded. If alternative splicing forms are 
generated at all, their amount lie below the detection limit.  
F.3.5 Impact of the promoter on altered gene expression 
As illustrated in Figure E-1, all variants that were used for the analysis of the influence of codon 
adaptation on protein production were expressed under the control of a heterologous CMV 
promoter. Our group analyzed the effects of synonymous codon usage in earlier studies for different 
cell lines and identified the CMV promoter as suitable for expression. Therefore, for consistency 
reasons it was decided to keep to that expression system and express the subgenomic reporter 
variants under control of the CMV promoter. As this system is of course highly artificial, selected 
variants were additionally analyzed under the control of the LTR promoter of HIV-1, reflecting the 
natural context of the gag gene. For this, selected variants were cloned into an expression vector 
with an LTR promoter. As expected, all 5’-3’ adapted variants that were analyzed (huA_wtBCDE, 
huABC_wtDE and huABCDE) showed expression already in the absence of Rev. Further, the beneficial 
effect of additive humanization was observed to be comparable to the expression of these variants 
under control of the CMV promoter. The wild-type variant of gag wtABCDE showed complete Rev-
dependency. The same was true for the variant wt1-75_hu76-1500, which contains the inhibitory 
motif at the 5’ part of gag. In general, comparison between the gag variants under control of the 
CMV- and LTR-promoter showed a strong correlation between the two different sets, indicating a 
negligible effect of the promoter used on observed expression data. Therefore, it can be excluded 
that the observed effects are attributed to the artificial system of the CMV promoter. 
 Future prospects  
Taken together, it was seen that codon adaptation influences gag gene expression on different levels. 
First, a positional effect was observed, since humanization at the 5’ part of gag was a precondition 
for enhanced expression levels. Especially the nucleotides surrounding the position 61-75 were 
identified as a core motif of an inhibitory sequence if they are present in their wild-type form. 
Without the inhibitory motif, an additive effect of humanization was observed on gag expression as 
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it was also observed in the egfp experiments. The higher the number of humanized nucleotides, the 
higher was the expression level. These findings were true on protein as well as RNA level. RNA 
amounts correlated strongly with protein levels for all analyzed variants, indicating a strong effect of 
humanization on regulation of transcript amounts, rather than an impact on translation. The RNA 
amount is controlled by various biological processes. The performed experiments showed that the 
main reason for altered transcript concentration were RNA stability and transcriptional efficiency. 
Both processes might be influenced by altered secondary structures induced by codon adaptation. 
To confirm this hypothesis a detection of a direct RNA-protein interaction would be helpful. RNAs in 
cells are associated with RNA-binding proteins. These interactions influence different processes like 
transport, localization and also stability [166] of RNA molecules. Therefore, RNA pull-down assays 
should be done to identify relevant proteins binding to these RNAs. For instance, Kula et al. identified 
MATR3 as a cellular cofactor of Rev activity by a method to explore the proteome associated with 
the nuclear HIV-1 RNAs. For this, they generated cell lines harboring an integrated provirus carrying 
RNA binding sites for the bacteriophage protein MS2. Flag-tagged MS2 was then used for affinity 
purification of the viral RNA [167]. Another aspect that would be of interest is how the partial codon 
adaptation would influence gene expression or even HIV-1 replication in a proviral system. As a first 
approximation to this question, the expression of selected variants was analyzed under control of 
HIV-1’s LTR promoter. Since viral replication clearly is a more complex process that is impacted by 
several processes like reverse transcription or timely highly regulated gene expression, examination 
of partially humanized variants in the proviral context would be of interest. However, it might be the 
case that enhanced and Rev-independent gag expression would result in replication-deficient 
viruses, since HIV-1’s gene expression is an extremely regulated processes and especially the timing 
of expression is crucial. Nevertheless, detailed characterization of the individual replication steps 
could help to elucidate the mechanisms involved in interpreting the information conveyed by 
sequences exhibiting different codon compositions.  
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G Appendix 
 Northern Blot analysis of 5’-3’-adapted variants 
As an additional validation of correct splicing and mRNA expression, northern blot analysis was 
performed for all 5’-3’-adapted variants. Additionally, mRNA was isolated from the nucleus as well 
as from the cytoplasm, to gain insight in export processes. 
 
Figure G-1: Northern blot analysis of 5’-3’-adapted variants 
HEK293T cells were transfected with the different variants and RNA isolation was performed after separation of nuclear and 
cytoplasmic fractions. Detection of gag mRNA and β-actin mRNA was performed by the usage of complementary RNA 
probes. 
As shown in Figure G-1 the general expression pattern of the 5’-3’ set was confirmed. Additional 
humanization led to enhanced expression of gag. All 5’-3’-adapted variants were expressed in the 
absence as well as in the presence of Rev. Wild-type gag was expressed in the cytoplasm only in the 
presence of Rev (a minimal band was detected). In the nucleus, an impaired but clearly detectable 
band was observed. Further, no cryptic splicing variants were detected for any of the partially 
humanized variants. 
 Comparison of p24 levels in the supernatant and intracellular p24 
levels of transfected HEK293T cells. 
To ensure that analysis of gag levels in the supernatants of transfected cells provide reliable insights 
into gag protein production, intracellular gag amounts and gag release into the supernatant were 
compared for a selected set of variants. For this, HEK293T cells were transfected with the adapted 
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gag variants. Gag protein production was quantified in the supernatants as well as cleared cell lysates 
of transfected cells after 48 hours by p24-ELISA. Transfection was performed with the 5’-3’adapted 
variants in the absence of Rev which span a broad range of p24 concentrations .
 
Figure G-2 Comparison of intracellular p24 amounts and p24 levels in the supernatant of transfected HEK293T 
 A) Schematic overview of the adapted variants and localization of humanized and wild-type nucleotides. B) Gag expression 
measured by p24-ELISA in supernatants or cell lysates of transfected HEK293T cells for 5’-3’-adapted variants after 
transfection of HEK293T cells. B) Correlation analysis of intracellular p24 levels (x-axis) and p24 levels in the supernatants 
(y-axis) of transfected HEK293T cells. 
Analysis of intracellular gag production showed very similar levels compared to the quantification of 
gag in the supernatant. The beneficial effect of humanization in dependency on the number of 
humanized nucleotides was observed in both fractions. All 5’-3’-adapted variants were expressed in 
the absence of Rev. The lowest p24 values were detected for huA_wtBCDE while the completely 
humanized variant huABCDE showed the strongest expression pattern. The comparability between 
intracellular p24 level and p24 expression in the supernatant becomes clear by calculating the 
correlation with each other. As shown in Figure G-2C the two parameters correlated very strongly 
(r2= 0.98) with each other. Therefore, all p24 expression analyses were performed only with 
supernatant of transfected cells.  
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